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Abstract of thesis (in English) 
Mitochondria have been implicated in the carcinogenic process because of their role in 
apoptosis and other aspects of tumor biology. Compared to nuclear DNA, 
mitochondrial DNA (mtDNA) is highly susceptible to damage and is limited in repair, 
so it has a much higher frequency in mutation. mtDNA mutations, especially in the 
displacement-loop (D-loop) have recently been reported in various malignancies. To 
assess the pattern of mtDNA mutations in HCC, the whole mtDNA genome in four 
HCC tissues and one cell line (Hep3B) were directly sequenced. All five cases 
displayed a C-tract mutation around the position of nucleotide 310 in the D-loop region 
(D310). Totally 150 alterations in both the D-loop and the coding regions were 
observed, which accounted for an alteration rate of 7.5 and 1.4 per one thousand base 
pairs, respectively. In an effort to further characterize the mutational changes in the 
D310 region and the coding region, 55 surgical HCC tissues and their corresponding 
non-tumorous liver tissues that were resected from Chinese patients were studied. The 
D310 region within the D-loop and the five genes encoding CytB, Coll, NDl , ND4, 
and ND5 within the coding region were investigated. PGR was first used to amplify 
•‘ these six regions, then mutations in the C-tract region were screened by PGR fragment 
length detection assay (PFLDA) and the mutations in five respiratory subunits genes 
were screened by single strand conformational polymorphism (SSCP). Subsequently, 
all cases with the C-tract mutations were subjected to direct sequencing. Twelve out of 
the 55 HCC cases (22%) analyzed harbored somatic deletions/insertions at the C-tract. 
Most of them (10 out of 12) were one base pair (bp) deletion (six cases) or insertion 
(four cases). The data suggested that the C-tract mutations of D310 revealed the genetic 
instability of mtDNA (mtGI), and the C-tract of 7 Cytosines(C7) was the most stable 
polymorphic type for Chinese HCC patients. Additional mutations and deletions were 
also found in the D-loop region. For the five respiratory chain subunit genes, 47.3% of 
CytB, 34.5% of ND4，29.1% of ND5, 21.8% of NDl and 16.4% of Coll were 
suggested to harbor mutations from SSCP analysis. Mutations in these five genes were 
subsequently confirmed by direct sequencing in 25 randomly selected cases (five for 
each genes), although no mutation hotspot was identified. These data suggest that 
mtDNA were frequently mutated in HCC and that the D-loop of mtDNA, in particular 
C-tract, is a mutational hotspot in Chinese HCC, and could potentially be used as a 
novel tumor marker. 
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論文摘要(中：^ 
中 國 人 肝 細 胞 癌 （ H C C ) 中 線 粒 體 D N A 突 變 的 硏 究 
最近，人們在多種惡性腫瘤中發現線粒體DNA,尤其是替代環（Displacement-
loop，D-loop)的突變。爲評估肝細胞癌中線粒體DNA突變情況’本論文首先 
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1.1 Hepatocellular carcinoma in general 
1.1.1 Epidemiology, and risk factors 
1.1.1.1 Incidence 
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors 
worldwide with an estimated 500,000 to one million new cases annually and it causes an 
estimated 1,250,000 deaths every year (Wards et al, 1991). The incidence ranges from 2 
cases per 100,000 of the population in USA to 150 cases per 100,000 of the population in 
parts of Africa and Asia where HCC accounts for a large proportion of cancer deaths. In 
Hong Kong, HCC ranks as the 2nd most common type of cancer. The annual incidence 
rate in 1984 was 35.4 per 100,000 for the male, and 8.9 per 100,000 for the female 
„population. The incidence has risen steadily over the last 30 years froml6.9 cases per 
100,000 in 1965 to 28.6 in 1984 to 35.4 per 100,000 in 1991 (Hospital Authority, Hong 
‘ K o n g 1995) while the mortality rate risen from 13 per 100,000 in 1961 to 19 in 1981 and 
to 21 in 2000(Hospital Authority, Statistical Report 2000-2001. Hong Kong, 2001). The 
incidence of HCC in surrounding regions, such as mainland China and Taiwan, are 
similar or even higher (The Editorial Committee for the Atlas of Cancer Mortality in 
PRC). Published census from the Department of Health in Taiwan in 1993 showed that 
cancer death was 107/100,000 population. HCC is the number one cause of cancer death 
with a mortality rate of 24.05/100,000 population. About 5,000 people die from hepatoma 
each year in Taiwan (Whang et al, 1998). 
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1.1.1.2 Race, sex and age distribution 
There is geographical /mcial differences in the incidence of HCC. It is the most common 
malignant tumor among males in western, middle and eastern Africa, the second common 
onset malignacy in southern Africa and sourth Asia, and the third most common among 
males in China. It is a relatively rare tumor in most parts of America, Europe, northern 
Africa and middle and eastern Asia. The incidence of HCC is higher in Asians and blacks 
with a age standardized incidence rate of more than 20 per 100,000 of the population. 
HCCs are more commonly found in males with a male to female ratio of 6:1 in Asia, 2:1 
in U.S.A. and 3:1 worldwide. The incidence increases in parallel to age. The mean age at 
diagnosis in high-risk areas such as Asia is about 10 years earlier (53 years) than those in 
the low risk areas like the U.S. (62 years) (Bosch et al 1991). 
,1.1.1.3 Predisposition 
HCC generally occurs in association with underlying chronic liver diseases. Cirrhosis is 
the essential precursor lesion of most HCC. Cirrhosis is defined as hepatic inflammation, 
an excess deposition of hepatic collagen accompanied by hepatocellular regeneration in 
the form of nodules. Chronic.liver disease induces fibrogenesis as a healing or repair 
mechanism but only a minority of patients develops cirrhosis, which probably results 
from a combination of continuing cell injury and genetic predisposition. As cirrhosis 
progresses, it-results in portal hypertension, liver failure or hepatocellular carcinoma 
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1.1.1.4 Risk factors and etiology 
Hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular 
carcinoma in our geographic area. Hepatitis B, and to a lesser extent hepatitis C chronic 
carriage are strongly associated with the development of hepatomas. Other risk factors 
include aflatoxin exposure, alcoholic liver disease, autoimmune chronic active hepatitis, 
genetic hemochromatosis, and hereditary tyrosinemia. Other liver inflammatory 
conditions such as alpha-1 antitrypsin deficiency are only moderately associated with 
HCCs, and conditions like primary biliary cirrhosis and primary sclerosing cholangitis is 
weakly associated with hepatomas (Tabor et al, 1991). 
1.1.2 Pathology and staging 
HCCs are typically described as nodular, diffuse or massive, more than 90% of HCC are 
massive or diffuse while the nodular type mainly present as multifocal lesions. Several 
histological types have been documented; these include hepatocytic, clear cell, 
pleomorphic cells, giant cells, spindle cells or granular cells. The staging of HCCs is 
based on primary tumor size, nodal, portal system and adjacent organs involvement and 
distant metastatic spread (Table .1). 
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Table 1. Staging for HCC 
Primary tumor -
j x Primary tumor can not be assessed 
TO No evidence of primary tumor 
Ti Solitary tumor 2 cm or less in the greatest dimension without 
vascular invasion 
j 2 Solitary tumor 2 cm or less in the greatest dimension with 
vascular invasion, or multiple tumors limited to one lobe, none 
more than 2 cm in greatest dimension, or solitary tumor more 
than 2 cm in the greatest dimension without vascular invasion 
T3 Solitary tumor more than 2 cm in the greatest dimension with 
vascular invasion, or multiple tumors limited to one lobe, none 
more than 2 cm in greatest dimension, with vascular invasion, 
or multiple tumors limited to one lobe, any more than 2 cm in 
the greatest dimension with or without vascular invasion 
T4 Multiple tumors in more than one lobe or tumor(s) involve(s) a 
major branch of the portal or hepatic vein(s) or invasion of 
adjacent organs other than the gallbladder or perforation of the 
, visceral peritoneum 
Regional lymph 
nodes 
Nx Regional lymph nodes can not be assessed 
NO No regional lymph node metastasis 
N1 Regional lymph node metastasis 
Distant metastasis 
Mx Distant metastasis can not be assessed 
MO No distant metastasis 
Ml - Distant metastasis 
Stage grouping 
Stage I TINOMO 
Stage II T2N0M0 
Stage IIIA T3N0M0 
Stage IIIB TINIMO 
T2N1M0 
T3N1M0 
Stage IVA T4 AnyNMO 5 
Stage IVB Any T Any N Ml 
1.1.3 Treatment 
The diagnosis of HCC could be made with a combination of blood test of alfa-fetoprotein 
level, radiologic imaging and confirmation of histology. Staging is essential for the 
management of HCC, as the choice of therapy depends on the functional state of the liver 
and the extent of tumor growth. Although several treatment modalities have been 
introduced for HCC, surgery, in the form of either hepatic resection or orthotopic liver 
transplantation (OLT) remains the only potentially curative treatment. Resection is the 
mainstay of treatment for HCC, especially for small, unifocal tumors. Unfortunately, less 
than 20% of patients with cirrhosis and HCC are surgical candidates. Contraindications to 
resection include advanced cirrhosis, multinodular liver involvement, portal vascular 
invasion extrahepatic metastases and other co-morbid conditions. Vascular occlusion 
techniques have improved the surgical outcome of hepatic resection. Adjuvant treatments 
. i n the forms of chemotherapy and intra-arterial therapy are used in combination with liver 
resection or OLT in order to improve outcomes (Colleoni et al, 1998; Mor et al, 1998; 
Bismuth er al, 1999). 
For patients with inoperable HCC, palliative treatment can be offered. Transcatheter 
arterial chemoembolization (TACE) is a targeted therapy that combines the delivery of 
chemotherapy at higher local concentration to tumor cells via hepatic artery together with 
arterial embolization to induce ischemic necrosis. Ideal candidates are those who have 
adequate liver function, a small HCC confined to the liver, in the absence of biliary 
abnormalities, impaired portal flow due to hepatofiigal flow or portal vein thrombosis. A 
survival benefit with TACE therapy has recently been demonstrated. (Trevisani et al, 
2001; Lo et al’ 2002). HCC Patients may also benefit from local ablative therapy, such as 
ethanol injection, hepatic artery embolization, and radio frequency ablation. Systemic 
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chemotherapy has been widely employed, especially for patients with metastases disease 
or for persistent or recurrent disease. However the efficacy has been limited with 
significant toxicity. To date, systemic combination chemotherapy has not been shown to 
be superior to single agent chemotherapy in survival (Johnson, 2003). The identification 
of new, effective chemotherapy drugs and other treatment modalities for advanced stage 
HCC is urgently required (Trevisani et al, 2001). Studies of radiation therapy for HCC 
(external beam and internally via intra-arterial injection) have not demonstrated a 
survival benefit. Tamoxifen (hormonal therapy) does not improve survival in large 
clinical trials (Castells et al, 1995; Riestra et al, 1998). Gene therapy is an exciting 
approach to treat HCC but at present, is largely confined to preclinical and experimental 
settings (Sangro et al, 2002). 
1.1.4 Improvement of early detection and treatment of HCC 
HCC is most often diagnosed at an advanced stage, occasionally with metastases. 
Advanced HCC has a dismal prognosis with a median survival of only 5 month (Bruix et 
al, 2001). Although screening with a combination of alpha-fetoprotein and 
ultrasonography surveillance in patients with chronic hepatitis has been conducted to 
detect early disease (Liaw et al, 1986; Chang et al, 1997), these screening methods are 
not sensitive enough, and cannot be applied to all populations at risk. There is a need 
need to find new tumor markers for the early detection of HCC. From clinical perspective, 
noninvasive investigation, which is easy to perform such as blood testing, is prefered. 
The identificatrion of molecular markers would rend this opportunity. 
Cancer including HCC is the result of a multistep mechanism that ends in malignant cell 
transformation. The earliest presentation in HCC tumorogenesis should be its molecular 
. 7 
transformation. But the molecular mechanisms of hepatocarcinogenesis are not well 
understood, although aneuploidy, and multiple genetic alterations are often present. For 
example, mutations of p53, Rb and B-catenin have been reported in HCC, while c-myc 
and cyclin D1 are frequently overexpressed (Murakami et al, 1991; Nhieu et al, 1999; 
Nishida et al, 1994). Loss of heterozygosity (LOH) may be associated with the 
inactivation of tumor suppressor genes. LOH at Ip, 4q，6q, 8p, 13q, 16q and 17p loci are 
frequently reported in human HCC (Nishida et al, 1992; Konishi et al, 1993;Kuroki et al, 
1995; De Souza et al, 1995). In addition, several growth factors have been implicated in 
the development of HCC, including transforming growth factor eyand 6 (Ito et al, 1991). 
Unfortunately, these fragmented findings do not piece together a clear portrait of the 
development of HCC. This disease has been referred to as very heterogeneous 
(Thorgeirsson et al, 2002). Despite the enormous progress made during the last decade in 
the understanding of the role of mismatch repair genes, oncogenes, and tumor suppressor 
,genes, several aspects in the process of hepato-carcinogenesis still remain unclear. 
Recently, frequent mitochondrial DNA (mtDNA) mutations have been found in various 
diseases including cancers. Its mutation rate is much higher than that of nuclear DNA 
(nDNA), so mtDNA mutations afford a massive effect over the nDNA mutation and may 
thus offer a more accessible target for the early detection of hepatocarcinogenesis. It has 
merged as a potential molecular tumor marker. Mutations in the mtDNA of tumor cells 
has focused the attention on these cytoplasmic organelles as concurrent factors in the 
initiation or progression of tumors (Shay and Werbin, 1987). Circulating liver tumor 
DNA alterations such as p 16 and p i5 methylation and mitochondrial mutations in the 
plasma and serum of HCC patients might be useful for early detection and monitoring of 
the disease (Ivy et al, 2000). Once mtDNA mutations are determined in HCC, similar 
technique might also be applied for its early detection and monitoring. 
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1.2 General aspects of mitochondria and niitochondrial DNA (mtDNA) 
1.2.1 General aspects of mitochondria 
1.2.1.1 General introduction of mitochondria 
Mitochondria are the powerhouse of the cell. They are present in virtually every cell in 
the body, with most cells containing about 2 to 10 mitochondria, depending on the 
individual cellular function. Mitochondria are organelles inside the cell, with the size 
similar to that of an Ecoli. bacterium. 
Mitochondria contain two very different membranes; an outer one and an inner one, 
separated by an intermembrane space. The surface area of the inner membrane is greatly 
increased by a large number of cristae, which protrude into the central space or matrix. 
In nonphotosynthetic cells, the principal fuels for ATP production are fatty acids and 
glucose. The complete degradation of glucose to CO2 and H2O is coupled to the synthesis 
of up to 36 molecules of ATP The initial stages of glucose degradation occur in the 
cytosol of the cell, where two ATPs are generated. Enzymes in the mitochondrial matrix 
and cristae carry out the terminal stages, including those involving oxidative 
phosphorylation (OXPHOS, phosphorylation coupled to final oxidation to oxygen). As 
many as 34 molecules of ATP are formed in the mitochondria, although this value can 
vary because much of the energy released in mitochondrial oxidation can be used for 
other purposes (e.g. heat generation), making less energy available for ATP synthesis. 
Similarly, virtually all the ATP formed during the oxidation of fatty acids to CO2 is 
9 
generated in the mitochondria. Thus, mitochondria can be regarded as the powerhouse of 
the cell (Nicholes and Fergusion, 1992). 
During the last few decades, people have realized roles of mitochondria in other cellular 
functions as well, for example, apoptosis (see review Desagher and Martinou, 2000), cell 
division (von Wangenheim and Peterson, 1998), and aging (Melov, 2000; Rustin et al, 
2000). The role of mitochondria in different kinds of human diseases has also begun to be 
understood. 
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1.2.1.2 Respirat ion chain of mitochondria 
Oxidative phosphorylation is mediated by five enzyme complexes that are embedded in 
the mitochondrial inner membrane (Table 2). The respiratory chain (or electron 
transportation chain, ETC) components are complexes 1, II, 111, and IV, in addition to the 
mobile components, coenzyme QIO (Q) and cytochrome c (Cyt C). Electrons produced 
from the oxidation of nutrients are carried by NADH or succinate and enter the 
respiratory chain at complex 1 (NADH dehydrogenase) or complex II (succinate 
dehydrogenase), respectively. Coenzyme QIO then accepts the electrons from either of 
these complexes and passes them to complex 111. Complex 111 transfers the electrons to 
cyt c, which then shuttles them to complex IV where the final acceptor is molecular 
oxygen to generate water. At complexes I, 111, and IV，the energy released by the 
electrons is used to pump protons (H+) to the outside of the mitochondrial inner 
membrane. This creates an electrochemical potential, which consists of a proton gradient 
and a membrane potential (m), which is positive on the outside and negative on the 
mitochondrial matrix side. Complex V (ATP synthase) uses the energy of the proton 
gradient generated at complexes 111, IV, and 1 and couples it to the phosphorylation of 
adenosine 5'-diphosphate (ADP) to produce ATP (Wallace, 1999). 
Complexes Respiratory Chain Complex Nuclear DNA Mitochondrial 
— 一 Subunits DNA Subunits 
I NADH-dehydrogenase complex 36 7 :NDl-6, ND4L 
II Succinate dehydrogenase complex 4 0 
III Ubiquinol-cytochrome c reductase 10 1 Cyt B 
complex 
IV Cytochrome c oxidase 10 3 Col,11,111 
V ATP synthase 14 2 ATPase 6,8 
Table 2.Respiration chain complexes. The number before the name of mtDNA subunits 
represents the number of the subunits. 
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As electrons flow through carriers within the respiratory chain complexes, superoxide (O2, 
sup,) can be generated as a byproduct by single electron reductions of molecular oxygen 
(Figure 1). Increased levels of reactive oxygen generation result from deficiencies in 
enzymatic activity of the respiratory chain complexes, either as an isolated defect or, in 
most of the cases, as part of a multiple respiratory chain defect. (Hardy et al，1991; 
Higuchi et al, 1998; Kruidering et al, 1997; Schapira, 1998). OXPHOS is the major 
endogenous source of the ROS (O2, sup,，H2O2, and OH[sup.])，which are toxic 
by-products of respiration. This is because when the ETC is inhibited, the electrons 
accumulate in the early stages of the ETC (complex I and CoQ), where they can be 
donated directly to molecular oxygen to give superoxide anion (O2, sup,). Superoxide 
anion is detoxified by the mitochondrial Mn superoxide dismutase (MnSOD) to give 
hydrogen peroxide (H2O2), and H2O2 is converted to H2O by glutathione peroxidase 
(GPx). H2O2, in the presence of reduced transition metals, can also be converted to the 
highly reactive hydroxyl radical (OH[sup.]) by the Fenton reaction. Chronic ROS 
exposure can result in oxidative damage to mitochondrial and cellular proteins, lipids, 
and nucleic acids, and acute ROS exposure can inactivate the iron-sulfur (Fe-S) centers of 
ETC complexes I，II, and III，and TCA cycle aconitase, resulting in shutdown of 
mitochondrial energy production (Wallace, 1999). 
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Figure 1. Mitochondrial electron transportation chain. Sources of electrons are provided 
by substrates to complex I (NADH) and complex II (succinate). The electrons (e ) are 
shuttled through the respiratory chain complexes (I-IV). Ubiquinone (Q) and cytochrome 
( Q are mobile carriers of electrons from one complex to the next. The energy stored in 
the electrochemical gradient generated by complexes I, III, and IV is used by ATP 
synthase (complex V) in the production of ATP (From Nhu-An Pham et al’ 2000) 
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1.2.2 The mitochondrial genome (from Taanman JW, 1999) 
1.2.2.1 Structure 
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Figure 2. The human mtDNA genome .The gene products encoded by the L-strand are 
shown in the inner complete circle and the gene products of the H-strand in the outer 
complete circle. The D-loop is shown as a three-stranded structure. The origins of 
H-strand (OH) and L-strand (OL) replication and the direction of DNA synthesis are 
indicated by long bent arrows; the initiation of transcription sites ( ITL , ITM，ITH2) and the 
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direction of RNA synthesis are denoted by short bent arrows. The binding site for the 
mitochondrial transcription terminator (mtTERM) is indicated. The 22 tRNA genes are 
depicted by dots and the single letter code of the amino acid (isoacceptors for serine and 
leucine are distinguished by their codon sequence). tRNAs are F, phenelalanine;V, 
Valine; L, leucine; Y，tyrosine; S, serine; D，aspartic acid; K, lysine; G, glycine; R, 
arginine; H, histidine; E, glutamic acid; T, tyrosine and P, proline. The genes coding 
for the two rRNA species (12S and 16S) and the 13 protein coding genes are depicted by 
shaded boxes. Leucine and serine each require two tRNAs, dedicated to different codon 
groups: Leu (UUR) and leu (CUN), and Ser (UCN) and Ser (AGY) respectively. ND, 
CO and ATPase refer to genes coding for subunits of NADH: ubiquinone oxidoreductase, 
ferrocytochrome c:oxygen oxidoreductase (cytochrome c oxidase) and FiFo-ATP 
synthase, respectively, whereas CytB encodes apocytochrome b of ubiquinol: 
ferricy to chrome c oxidoreductase. The abbreviation used are: D-loop, Displacement loop; 
C-tract，Poly-cytosine tract; CytB, Cytochrome b; NDs: subunits of NADH 
dehydrogenase; COs: subunits of cytochrome c oxidase. 
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A human cell contains thousands of copies of mitochondrial DNA but the total 
mitochondrial DNA complement represents only 0.5% of the total DNA in a nucleated 
cell. The human mtDNA is a double-stranded circular molecule (Figure 2.) which 
contains 16,569 nucleotide pairs, except for D-loop (displacement loop) which is triple 
stranded due to the synthesis of an additional piece of the heavy (H) strand (7 SDN A). It 
is very compact, and composed of little non-coding sequence, essentially just the l，025bp 
D-loop, and coding region encoding even some overlapping genes. Most information is 
encoded on the H strand, with genes for two rRNAs, 14 tRNAs, and 12 polypeptides. The 
light (L) strand codes for eight tRNAs and a single polypeptide. All 13 protein products 
are constituents of enzyme complexes of oxidative phosphorylation system. The 
non-coding region that includes the D-loop is located between two tRNA genes, F and T. 
Oh is the origin of heavy strand replication, O l is the origin of light strand replication 
(Anderson et al, 1981). 
1.2.2.2 Genes for structure proteins 
MtDNA encodes for 37 genes including 13 of mitochondrial peptide subunits. All the 13 
peptides are in mitochondrial respiratory-chain (OXPHOS). The remaining 67 OXPHOS 
subunits are nuclear encoded. Subunits I, II and III of cytochrome c oxidase are encoded 
by COI, c o n and COIII. One subunit of cytochrome b is encoded by CYTB gene. 
Seven subunits of NADH dehydrogenase are encoded by NDl-6 and ND4L (Attardi 
et al, 1986; Chomyn et al, 1986). The Fo portion of the ATP synthase has two 
mitochondrialiy-encoded subunits, ATP6 and ATP8 (Mariottini et al, 1983). 
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1.2.2.3 Genes for translation 
MtDNA codes all the RNAs needed for mitochondrial translation in humans. The 
mitochondrial mRNAs are translated within the mitochondrion on 
chloramphenicol-sensitive ribosomes using mtDNA-encoded rRNAs and tRNAs. The 
mammalian mtDNAs share a unique genetic code where UGA = tryptophan, AGA and 
AGG = stop, and AUA = methionine. There are two rRNAs encoded by 12S and 16S 
rRNA genes respectively. A set of genes for 22 transfer RNAs is found in human mtDNA. 
All of them located between every 2 rRNA or Protein coding genes. No other tRNAs are 
known to be imported into mitochondria from outside. Leucine and serine each require 
two tRNAs, dedicated to different codon groups: Leu (UUR) and leu (CUN), and Ser 
(UCN) and Ser (AGY) respectively, while other amino acids requires only one tRNA to 
read their codons. Extended wobble rules make this possible (Barrell et al, 1980). 
1.2.2.4 Imported proteins and RNAs 
All the other proteins are encoded by the nucleus, including proteins needed for the 
respiratory chain, nucleotide translocation, ion transport, the niitochondrial DNA 
replication and transcription machinery, and all the proteins of the mitochondrial 
ribosome and its associated translation factors. These proteins are imported into the 
mitochondria after being synthesized in the cytosol through the Tom and Tim complexes 
(Schatz，1997; Sirrenberg，1996, 1998; Bauer et al, 2000), with the help of both 
cytoplasmic and mitochondrial heat-shock proteins. 
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1.2.3 mtDNA Maintenance 
Unlike nuclear DNA, mtDNA is continuously replicated. Thus, somatic mtDNA damage 
potentially causes more mtDNA mutations than somatic nuclear DNA damage does. 
Accordingly, DNA repair systems in mitochondria would actually be more important than 
those in nuclei. The enzymes responsible for mtDNA repair have been identified and are 
encoded by the same genes as their nuclear counterparts. Mitochondrion-targeting 
sequences (MTS) are generated through alternative splicing of mRNAs, alternative use of 
transcription initiation sites, or alternative use of translation initiation sites. In addition to 
DNA repair, the degradation of damaged mtDNA may be tolerated because there are 
multiple copies of mtDNA molecules in a cell. 
1.2.3.1 Base excision repair 
A small amount of base damages that do not distort the DNA helix can be repaired by 
Base Exchange repair (BER). Alterations include deamination of cytosine to uracil, 
alkylation (e.g. to 3-methyl adenine), oxidative modification of bases (e.g. to 8-oxoG)， 
and errors in DNA replication (e.g. misincorporation of dUTP). The BER pathway is 
initiated by DNA glycosylases that recognize a modified base, cleave the N-glycosylic 
bond between the base and the deoxyribose, and leave an apurinic (AP) site. 
1.2.3.1.1 DNA glycosylases 
Uracil DNA glycosylase is the first DNA glycosylase identified in the mitochondria. 
Uracil DNA glycosylase removes uracil that may arise in DNA, either by deamination of 
cytosine or by the incorporation of dUMP during DNA replication. The former situation 
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gives rise to C/G to T/A transition mutations upon DNA replication. Mammalian cells 
contain two known isoforms of uracil DNA glycosylase derived from the UNG genes: 
UNGl and UNG2, which are situated in mitochondria and nuclei, respectively (Burgers 
and Klein, 1986). 
12.3.1.2 8-OxoG-recognizing DNA glycosylases 
As mtDNA is under strong oxidative stress, the repair of oxidatively modified bases by 
BER is of particular importance. It is worth noting that AP site can also be generated by 
ROS per se. The AP sites and single-strand breaks can also be repaired in the BER 
pathway. Among the types of oxidative base modifications, 8-oxoG is the most common 
and is also the most important one for inducing mutations (Sekiguchi, 1996). Both dAMP 
and dCMP are incorporated with equal efficiency during replication replacing 8-oxoG. 
-The misincorporation of dAMP induces C/G to AIT trans version mutations. Bacteria 
contain elaborate mechanisms to counteract the mutagenic effects of 8-oxoG (Michaels 
and Miller 1992). Oxidized purines, such as 8-oxoG and 2-hydroxyadenine, are repaired 
by MutM and MutY homologues. In Escherichia coli, two DNA glycosylases encoded by 
mutM and mutY genes repair DNA containing 8-oxoG. The MutM protein (8-oxoG DNA 
glycosylase/fpg protein) removes 8-oxoG paired with cytosine; and MutY (adenine DNA 
glycosylase) removes adenine paired with 8-oxoG in DNA. MutM also excises 
ring-opened purine (formamide pyrimidine, fapy), another oxidatively damaged base, and 
for this reason is also termed fpg protein. 
The yeast OGGl gene encodes a DNA glycosylase that functionally complements the 
defect of E. coli MutM (Nash et al, 1996). The human homologue of yeast OGGl, 
hOGGl, has been cloned. Seven spliced variants of hOGGl have been reported 
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(Nishioka et al 1999). Among them, types la and 2a are major forms, which are 
transported to nuclei and mitochondria, respectively. Type la contains a 
mitochondrion-targeting signal (MTS) at the N-terminus and a nuclear localization signal 
(NLS) at the C-terminus. Type 2a loses the C-terminal NLS and may be targeted to 
mitochondria. It is suggested that the mitochondria depend more on OGGl than do nuclei 
for the elimination of 8-oxoG, for HeLa cells where hOGGl was specifically 
overexpressed in mitochondria showed enhanced oxidative damage repair and better 
cellular viability against oxidative challenge (Dobson et al, 2000). 
The human mutY homologue, hMYH, was cloned (Slupska et al, 1996). The hMYH 
proteins of 52 kDa and 53 kDa proteins were delected in the nucleus and the 57 kDa 
protein was found in mitochondria in Jurkat cells (Ohtsubo et al, 2000). hMYH 
efficiently excises both 2-hydroxyadenine, an oxidized form of adenine paired with 
'guanine, and adenine paired with 8-oxoG or guanine. 2-Hydroxyadenine, wherein the C2 
position is oxidized, is produced by ROS in vitro and in vivo (for a review, see Kamiya 
and Kasai, 2000). And it elicits various types of mutations in sequence- and host 
cell-dependent manners, thereby suggesting that it can pair with all four bases (Kamiya 
and Kasai, 1997). 
1.2.3.1.3 Thymine glycol DNA glycosylase 
Oxidized pyri'midines, like thymine glycols, urea, and cytosine hydrates, are primarily 
excised by endonuclease III family proteins (Endolll, thymine glycol DNA glycosylase). 
NTGl and NTG2 are genes for S. cerevisiae homologues of E. coli EndoIII. A 
Ntgl-green fluorescence protein (GFP) fusion protein localizes primarily in mitochondria, 
whereas Ntg2-GFP localizes in nuclei (You et al, 1999). 
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1.2.3.1.4 3 -Methyl adenine DNA glycosylase 
Alkylating agents are produced in the environment and are formed in vivo, e.g. 
S-adenosylmethionine. Mitochondria apparently lack nucleotide excision repair, which 
plays a primary role in repairing alkylated bases in nuclei. Yet, certain types of alkylated 
mtDNA are repaired (Myers et al, 1988; Satoh et al, 1988; LeDoux et al, 1993). DNA 
glycosylases for alkylated bases are called 3-methyl adenine DNA glycosylases, because 
3-methyl adenine was the first substrate to be identified (Lindahl, 1976). However, many 
other damaged purines, including 3-methyl adenine, 3-methyl guanine, 7-methylguanine, 
7-methyladenine, and hypoxanthine, are also the main substrates for human and S. 
cerevisiae enzymes, MPG and Mag, respectively (Krokan et al, 1997). Human MPG, but 
not yeast Mag, removes 8-oxoG. In nuclei, MPG- deficient and nucleotide excision repair 
could compensate (Elder et al, 1998). 
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1.2.3.1.5 AP endonucleases 
AP sites are left after base excision by DNA glycosylases. AP sites can be generated by 
spontaneous destabilization of the N-glycosylic bond between the base and the 
deoxyribose sugar. This destabilization is frequently caused by ROS. A major human AP 
endonuclease is encoded by APEl/Ref-1. APEl has another important function in the 
redox-mediated activation of oxidized transcription factors. For this reason, it is also 
designated Ref-1 (reducing factor; Xanthoudakis et al, 1992). Human APEl localized in 
both nuclei and mitochondria (Tell et al, 2001). APEl does not have a classic 
mitochondrial N-terminal presequence, so the epitope-tagged APEl failed to be targeted 
to mitochondria (Takao et al, 1998). Although the role of APEl as a reducing factor in 
mitochondria is not well understood, thioredoxin (which can modulate APEl redox 
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activity) also locates in mitochondria (Ejima et al, 1999). In addition, APEl is involved 
not only in the repair of damaged DNA but also diminishes exposure to oxidative stress 
per se because heterozygous animals manifested elevated levels of oxidative markers, 
such as lipid peroxides in serum. Recently, a second human AP endonuclease, APE2, was 
cloned (Hadi and Wilson, 2000). APE2 has a functional N-terminal MTS and is localized 
in mitochondria, although predominantly in the nucleus (Tsuchimoto et al, 2001). Human 
APE2 has class II AP endonuclease activity in vitro. However, the activity is much 
weaker than that of APEl (Hadi and Wilson, 2000); and the functional significance in 
mitochondria is unknown. 
1.2.3.1.6 DNA polymerase 
In nuclei, DNA polymerase beta, which has dRPase activity, is mainly responsible for the 
-BER pathway. Human DNA polymerase gamma can remove dRP and fill one nucleotide 
gap (Longley et al, 1998a, b), suggesting that polymerase gamma also functions for DNA 
repair. BER was reconstituted in vitro with mitochondrial enzymes, including polymerase 
gamma (Pinz and Bogenhagen, 1998). 
1.2.3.1.7 DNA ligase 
For the completion of BER, gapped DNA must be ligated by DNA ligase. DNA ligase 
activity purified from X. levis mitochondrial extracts was immunologically related to 
nuclear DNA ligase III (Pinz and Bogenhagen 1998). The DNA ligase III gene, LIG3, 
encodes a mitochondrial form of the protein through an alternative translation initiation 
site (Lakshmipathy and Campbell, 1999a, b) and is essential for maintenance of mtDNA 
(Lakshmipathy and Campbell, 2001). 
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1.2.3.2 Recombinational and mismatch repair 
Double-strand breaks are usually repaired by recombinational repair. Yeast mitochondria 
are very active in recombination (Contamine and Picard, 2000). Several evidences 
support DNA recombination in mammalian mitochondria. Cisplatin-induced inter-strand 
DNA cross-links, which are repaired through homologous recombination in nuclei, are 
repaired in mammalian mitochondria (LeDoux et al, 1992). Large-scale rearrangements 
of human mtDNA [i.e. kilobase-sized partial deletions (del-mtDNAs) and duplications 
(dup-mtDNAs)], together with wild-type mitochondrial genomes (wt-mtDNAs), have 
been associated with a number of human disorders. In any one patient harbouring both 
del- and dup-mtDNAs, the two coexisting rearranged species are always topologically 
related. The dup-mtDNA can be thought of as being composed of a wt-mtDNA and a 
del-mtDNA arranged head-to-tail. Prolonged culture of cells that contained initially 
'100% dup-mtDNAs generated equimolar wt- and del-mtDNAs (Tang et al, 2000). It is 
likely that intramolecular homologous recombination of dup-mtDNAs gave rise to the 
wt- and del-mtDNAs (Holt etal, 1997). 
1.2.3.3 Elimination of pre-mutagenic free nucleotides 
Oxidative DNA damage also occurs at the level of free nucleotides. Oxidized 
deoxygunanine nucleotide, 8-oxo-dGMP, is incorporated against adenine in DNA as 
efficiently as against cytosine during DNA replication, thus causing A/T to C/G 
transversion mutations (Sekiguchi, 1996). Therefore, elimination of this premutagenic 
8-oxo-dGTP is an essential part of the DNA repair system for oxidized guanine. Human 
hMTHl encodes proteins localizing both to the cylosol and to the mitochondria (Kang et 
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al, 1995). hMTHl efficiently hydrolyses 2-hydroxy-dATP (Fujikawa er a/, 1999). In vitro, 
2-hydroxy-dATP is about 12-fold more efficiently formed from dATP than 
2-hydroxyadenine is formed in DNA. Thus 2-hydroxyadenine in DNA is mainly derived 
from misincorporation of 2-hydroxy-dAMP during replication (Kamiya and Kasai, 2000). 
Intracellular GTP is much more abundant than dGTP 8-oxoGTP can cause transcription 
error (Taddei et al, 1997). hMTHl can hydrolyse 8-oxoGTP (Hayakawa et al, 1999). 
dUTP is a substrate for DNA synthesis and is incorporated against adenine. The 
incorporation of dUMP against adenine itself is not mutagenic. However, the A/U pairs 
are cleaved by uracil DNA glycosylase and thus give rise to AP sites or single-strand 
breaks that are potentially mutagenic. Usually dUTP is hydrolysed to dUMP by strong 
dUTPase activity and thus the incorporation of dUMP is minimized. The same gene 
encodes the nuclear and mitochondrial isoforms of human dUTPase, with 
isoform-specific transcripts arising via alternative transcription initiation (Ladner and 
-Caradonna, 1997). 
1.2.3.4 Selective degradation of damaged mtDNA 
Mitochondria are considered capable of abandoning damaged mtDNA and can tolerate 
DNA damage, owing to multiple copies of mtDNA (Chinnery et al, 1999). The 
degradation loss of mtDNA must be paid off lo maintain its copy number. Continuous 
replication of mtDNA in non-dividing cells, which may protect mtDNA from the 
accumulation of a critical threshold of mutations, supports this notion. Mammalian 
endonuclease G could be a nuclease for selective degradation, because it preferentially 
cleaves oxidatively damaged DNA (Ikeda and Ozaki, 1997). Although selective 
degradation of damaged DNA in mitochondria has not yet been proven, it could play a 
major role in preventing the accumulation of mutations and thus maintain mtDNA 
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integrity. 
In Conclusion, MtDNA is considered to suffer much more extensive oxidative damage 
than does nuclear DNA. It may need to consider which repair or degradation pathway 
mainly contributes to the maintenance of mtDNA integrity. 
1.2.4 Mitochondrial DNA replication 
Currently there are two models to address how mtDNA is replicated. One is a 
strand-asynchronous, asymmetric mechanism (Clayton D A, 1982). DNA synthesis starts 
in origin of replication of heavy strand (OH) adjacent to the D-loop and procedes by 
strand displacement unidirectionally 2/3 of the way around the genome to the origin of 
replication of light strand (OL) (Figure 3 and Figure 4). 
Each strand is transcribed from one predominant promoter, LSP (light strand promoter) 
and HSP (heavy strand promoter). Both are located in the control region that includes the 
displacement (D)-loop. The D-loop is a triple-stranded region generated by the synthesis 
of a short piece of H-strand DNA, the 7S DNA H-strand DNA replication is initiated 
within the D-loop 7S DNA at four major and three minor sites. Three of these correspond 
to L-strand transcription stop sequences at the conserved sequence blocks (CSB) I to III 
in the D-loop. The most prevalent 7S DNA starts at CSB-II. Primers for 7S DNA 
synthesis at this site are thought to be generated by the cleavage of the L-strand transcript 
by RNAse MRP (mitochondrial RNA processing enzyme), which includes a nuclear 
encoded RNA that appears to guide the cleavage of the RNA al the CSB-II (Chang DD 
and Clayton DA, 1987 a; b; 1989; Clayton DA, 1994). The bi-directional mitochondrial 
transcription factor (mtTFl) binds throughout the D-loop with a 40 to 50 base periodicity, 
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with MTCSB2 and MTCSB3 being unbound and MTCSBl being strongly bound. The 
mtTFl phasing downstream from MTCSBl corresponds to DNA synthesis initiation sites 
suggesting the mtTFl may play a role in defining the transition from RNA to DNA 
(Fisher et al, 1987). All 7S DNA molecules end at nucleotides just past the termination 
associated sequence (TAS), which interacts with sequence-specific binding factor(s) 
(Madsen et al, 1993). H-strand replication proceeds around the L-strand, displacing the 
single-stranded, parental H-strand. After traversing 2/3 of the genome, the L-strand origin 
is exposed. L-strand replication is then initiated with a specific primase containing the 
cytosol 5.8S rRNA (Wong et al, 1986) and proceeds back along the displaced H-strand 
template. 
After displacing the second origin of replication, OL，single stranded mtDNA synthesis 
starts in opposite direction. Recently, it was found that biased incorporation of 
ribonucleotides on the mitochondrial L-strand accounts for apparent strand-asymmetric 
DNA replication. It has been shown that bona fide replication intermediates from highly 
purified mitochondria are essentially duplex throughout their length, but contain 
widespread regions of RNA: DNA hybrid，as a result of the incorporation of 
ribonucleotides on the light strand which are subsequently converted to DNA. 
Ribonucleotide-rich regions can be degraded to generate partially single-stranded 
molecules by RNase H treatment in vitro or during DNA extraction from crude 
mitochondria. Mammalian mitochondrial DNA replication thus proceeds mainly, or 
exclusively, by a strand-coupled mechanism (Yang MY et al, 2002). 
The other model (Holt et al, 2000) represents a more conventional replication pathway. 
The model proposes that replication starts from a single origin and that the leading and 
lagging strands are synthesized simultaneously. The occurrence of two different classes 
of mtDNA replication intermediate raises many questions regarding the mechanisms by 
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which mtDNA replication is regulated in different physiological and developmental 
contexts. As a first step toward understanding how mtDNA synthesis might be regulated 
in situations where copy number is actively modified, Holt et al additionally investigated 
the representation of mtDNA replication intermediates in cultured human cells in which 
mtDNA amplification was induced by prior depletion via drug treatment. These 
replication intermediates were compared with those present in growing cells where only 
maintenance synthesis of mtDNA was taking place. Replication intermediates that were 
detected during reamplification of mtDNA were almost exclusively of the double-
stranded class. These are inferred to be the products of the conventional coupled leading-
and lagging-strand replication, initiating unidirectionally from the same origin detected in 
placenta. By contrast, in growing cells undergoing mtDNA synthesis merely to maintain 
copy number from one cell generation to the next, the predominant mtDNA replication 
intermediates were partially single-stranded, as predicted by the orthodox 
‘strand-asymmetric model. These findings indicate that different modes of mtDNA 
synthesis operate in human cells under different conditions, depending on whether copy 
number is being modulated or merely maintained. 
So far, rather little is known about the mitochondrial DNA replication machinery. The 
mtDNA polymerase (Pol y) elongates mtDNA during replication. It contains a catalytic 
subunit that possesses 5' to 3' DNA polymerase activity and 3' to 5' exonuclease 
proofreading activity (Foury et al, 1992). 
Animal Poly that copurifies with a smaller subunit (25 - 45 kDa) is called an accessory 
subunit. The addition of the human subunit to X. laevis Pol y catalytic subunit improves 
the processivity of DNA synthesis and enhances the affinity of the complex for primer 
termini (Carrodeguas et al, 1999). Recently, it has been demonstrated that the human 
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Hp55 subunit specifically binds double-stranded DNA and increases the affinity of Poly 
for DNA as well as the DNA synthesis processivily (Lim et al, 1999). The subunit may 
be involved in primer recognition and acts as a processivity clamp (Lim et al, 1999). 
There are many other factors involved in mtDNA replication. Human mitochondrial 
single-stranded DNA binding protein (SSB) SSB cDNA was cloned (Tiranti et al, 1993) 
and shown to encode a tetrameric protein with physicochemical properties analogous to E. 
coli SSB. This 13 kDa protein acts as a homoletramer and is essential for mtDNA 
maintenance but not for cell viability. 
Genes of three other typical DNA replication factors, heli cases, topoisomerases and DNA 
ligases, are still to be characterized in mitochondria (Lahaye et al, 1991; Schulz et al, 
1994). Recently, it has been shown that the human DNA ligase III gene encodes both 
nuclear and mitochondrial enzymes. The latter form contains a mitochondrial 
‘presequence translated from an in-frame ATG present upstream of the putative initiation 
start site (Pinz et al, 1998; Lakshmipathy et al, 1999). While this enzyme has been shown 
to be involved in mtDNA repair, its role in mtDNA replication has not been addressed 
(Wilier etal, 1999). 
In mammalian mitochondrial systems, all of the proteins known to be involved in DNA 
replication are encoded in the nucleus. Thus alterations and deficiencies in mtDNA 
replication must arise from mutations in mtDNA regulatory sequences and nuclear gene 
defects. 
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A . HSP B . HSP4k 
Figure 3. Schematic representation of human mtDNA replication mechanism (from 
Taanman JW, 1999). (A) An RNA molecule is synthesized from LSP using L-strand as 
template. This R N A molecule is cleaved in Oh by an RNase H-like activity and used as a 
primer by Pol T to extend a new DNA chain (H-strand). Several cleavage sites and 
RNA—DNA transition sites have been reported, up to downstream of CSBL (B) 
Elongation of the new H-strand by Pol Tproceeds. A primase synthesizes a primer at OL, 
which is used to initiate the synthesis of a new L-strand by Pol Twhen O l is exposed as 
single strand by the replication fork originating from OH. Thick and thin circles represent 
DNA H-strands and L-strands, respectively. Dotted lines represent R N A primers. Black 
arrows show the orientation of HSP and LSP. White arrows show the direction of 
replication by Pol 7 . 
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1.2.5 Mitochondrial DNA transcription 
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Figure 4. Schematic representation of the initiation of transcription and replication of 
human mtDNA (from Taamnan JW, 1999). The genes encoding 12S rRNA, tRNA ^^ ^ and 
tRNAPro are indicated with boxes on the H- and L-strands. Bent arrows indicate 
transcription initiation sites and direction of synthesis, dotted lines represent synthesised 
RNA. In the D-loop region (the 1118-bp sequence between nucleotides 577 and 16028), 
two major transcription initiation sites are present. Transcription initiation site ITHI， 
encompassed by the H-strand promoter (HSP), directs the transcription of the H-strand, 
whereas transcription initiation site ITL, encompassed by the L-strand promoter (LSP), 
directs the transcription of the L-strand. A second, minor transcription initiation site (ITm) 
for H-strand transcription is located in the gene for tRNA'''^ ® near the boundary with the 
12S rRNA gene. Enhancer elements upstream of the HSP and LSP that are known to bind 
the mitochondrial transcription factor mtTFA are indicated. A short (RNA) transcript 
originating at ITL serves as a primer for replication of the (leading) H-strand. Transitions 
from RNA to DNA occur within the dashed line, in the region around the conserved 
sequence blocks (CSBs) I，II and III. Oh is the origin of H-strand synthesis. Short DNA 
strands that are part of the triplex D-loop structure terminate near the 
termination-associated sequence (TAS). 
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Human mtDNA transcription initiation sites and promoter regions have been determined. 
There are two major transcription initiation sites ITHI (heavy-strand transcription 
initiation sitel) and ITL (light-strand transcription initiation site) situated within 150 bp 
of one another, and 3 promoters HSPl (heavy-strand promo tor 1)，HSP2 (heavy-strand 
promotor 2), and LSP (light-strand promoter) in the D-loop (Figure 4). Most genes in the 
mtDNA coding region are transcribed by the HSP1 that produces complete symmetric 
transcription of heavy strand of mtDNA while LSP produces symmetric transcription of 
light strand. HSP2 acts with binding sites for a transcription factor, mTERF, syntheses 2 
rRNAs. Transcription started by promoters binding with mitochondrial RNA polymerase 
and specificity factor (mtTFA) (Clayton, 1992; 2000). There are two polycistronic 
transcription units of heavy -strand (Montoya et al, 1983), a 2.7 kb unit containing the 
ribosomal RNA genes and the phenylalanine) and a 16.5 kb long unit, including both 
rRNAs, 13 tRNAs (all but phenylalanine) and valine tRNAs. There are four polypeptides, 
‘namely the ATP8, ATP6，ND4L and ND4; they are translated from bicistronic mRNAs. 
The remaining 8 tRNAs and one mRNA (ND6) are translated from the L-strand. In most 
cases, the 3'-end nucleotide of the individual mRNA coding sequences has been found to 
be immediately contiguous to a tRNA gene or another mRNA coding sequence, 
according to the punctuation model of mitochondrial transcription (Ojala et al, 1981). 
Once the RNA polymerase passes the 16S rRNA/tRNA^'"^^^^ boundary, H-strand 
transcription appears to be straightforward. The initiation and processing of the 
transcription sites and direction of synthesis are indicated in the Figure 4 Precise 
endonucleolytic excision of the tRNAs from the nascent transcripts will concomitantly 
.yield correctly processed rRNAs and, in most cases, correctly processed mRNAs (Ojala 
et al, 1981). An enzyme to recognize and cleave exactly both 5'-and 3'- termini of 
tRNAs is essential for this model. RNAase P can cleave the 5'-end(Doersen et al, 1985; 
Schon, 1999) and 3'-processing activity has been found (Manam and van Tuyle, 1987). 
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In addition, other RNA processing enzymes are needed. Post-transcriptional 
polyadenylation terminates the rRNA and mRNA sequences and 3'-terminal CCA is 
added posttranscriptionally to tRNAs (Dubin et al, 1982). Other RNA modification 
occurs as well (Gillham, 1994). 
The factor mediating attenuation of transcription has been termed mTERF (Kruse B.te al. 
1989) and is known to induce bending of the DNA helix. It plays an essential role in the 
control of the transcription of the rRNA and mRNA precursors. In vitro transcription 
studies have shown that mtTERM bound to its mtDNA target site functions 
bidirectionally and shows an even greater elTiciency of termination in the reverse 
orientation relative to the promoter site (Christianson et al, 1986). Thus, in addition to an 
attenuation function for H-strand transcription, mtTERM may halt L-strand transcription 
at a site where no L-strand encoded genes are found downstream (Figure 4). Bound 
mtTERM probably stops elongation of transcription by constituting a physical barrier, 
rather than by a specific interaction with the mitochondrial RNA polymerase, because 
- m t T E R M also mediates termination of transcription by heterologous RNA polymerases (J. 
Shang and Clayton, 1994). 
1.2.5 Mitochondrial DNA translation 
Details of the mitochondrial translation protein biosynthesis are so far poorly understood. 
Early indications of the prokaryotic origin of mitochondria came from observations that 
the spectrum of antibiotics inhibiting mitochondrial protein synthesis resembles that of 
prokaryotic systems (P. Borst and L.A, 1971). Nearly all elements of the mitochondrial 
translation machinery and mitochondrial protein synthesis are distinct from cytosolic 
translation or bacterial systems. Mitochondrial ribosomes contain less RNA and more 
proteins than bacterial ribosomes (Pietromonaco et al, 1991). Using mtDNA- encoded 
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rRNAs and tRNAs, human mitochondrial mRNAs are translated within the 
mitochondrion on chloramphenicol-sensitive ribosomes. The mammalian mtDNAs have 
a unique genetic code where UGA codes for tryptophan instead of being a stop codon, 
and AUA for methionine instead of isoleucine. GAA and AGG are stop codons instead 
of coding for arginine (Barrell et al, 1979). The wobble rules of Crick (Crick, 1996) are 
relaxed allowing a single tRNA to recognize each of the families of four triplets coding 
for a single amino acid. Several modifications occur in the human tRNAs (Sprinzl et al, 
1998). In addition, an unidentified modification of uracil at the wobble site in tRNA-Leu 
(UUR) has been found (Yasukawa et al, 2000). The sequences of mitochondrial tRNAs 
differ from the common type at many positions. The length of both the V¥C and 
dihydrouridine (DHU) loops vary considerably in mitochondrial tRNAs. An extreme 
example is tRNA-Ser (AGY), where the DHU loop is lacking completely. Some mRNAs 
lack AUG start codon. Instead AUN and sometimes GUG codons serve as sites for 
‘translational initiation. Translation starts with IMet-tRNA and the start process is 
intriguing because mammalian mitochondrial mRNAs have no upstream leader 
sequences to facilitate ribosome binding, unlike prokaryolic and eukaryotic cytosolic 
messengers. The translation starts at or very near the 5'-end with the codon for the 
initiating A^-formylmethionine (Montaya et al, 1981). In addition, the 5-termini of 
mitochondrial mRNAs lacks a 7-methylguanylale cap structure (Van den Bogert et al, 
1993). This excludes cap recognition and scanning mechanism for directing the ribosome 
to the initiation codon. The low translational efficiency of mitochondrial messengers 
(Cantatore et al, 1987) may in fact be the result of the absence of a 5'-end ribosome 
.recognition site and necessitate the observed abundance of mitochondrial messengers 
(Van den Bogert et al, 1993; Garstka et al, 1994) to ensure that a sufficient level of 
translation occurs. 
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After binding of the small ribosomal subunit to the messenger, the subunit is assumed to 
move to the 5'-end of the mRNA mediated by yet unspecified auxiliary initiation factors 
of mtDNA (mtIF). The only initiation factor identified in mammalian mitochondria to 
date is mtIF-2 (Liao and Spremulli, 1990). This monomeric protein factor belongs to the 
family of GTPases and promotes fMet-tRNA binding to the small ribosomal subunit in 
the presence of GTP and a template, which is reminiscent of the bacterial factor IF-2 
(mtIF-2). MtIF-2 bind to the small ribosomal subunit prior to its interaction with GTP, 
however, GTP enhances the affinity between mlIF-2 and the small subunit and allows 
fMet-tRNA to join the complex. Hydrolysis of GTP is thought to facilitate the release of 
mtIF-2 and the concomitant association of the large (39S) ribosomal subunit to form the 
55S initiation complex (Liao and Spremulli, 1991). 
Three mitochondrial elongation factors, mtEF-Tu, mlEF-Ts and mtEF-G, have been 
purified (Schwartzbach et al, 1989; Chung and Spremulli, 1990). The gene for human 
mtEF-Tu has been mapped to chromosome 16ql 1.2. The in vitro characterizations of the 
‘ p u r i f i e d factors and the cDNA sequence information have revealed striking similarities 
with the corresponding prokaryotic factors. Consequently, elongation of the nascent 
mitochondrial polypeptide is assumed to proceed in a similar fashion as in E. coli. 
mtEF-Tu combines with aminoacylated tRNAs and GTP to form a tightly associated 
ternary complex, which then deliver the tRNA to the receptor site of the milochondrial 
ribosome. Unlike the bacterial complex, it cannot be readily dissociated by guanidine 
nucleotides alone. Ribosome translocations are catalysed by mtEF-G. mtEF-Ts 
regenerates the EF-Tu.GTP complex from EF-Tu.GDP (Nierhaus, 1996). It has recently 
been demonstrated that the mtEF-Tu-Ts complex will dissociate in the presence of GTP 
and charged tRNAs (Woriax et al, 1997). Mitochondrial release factor 1 (mRF-1) 
34 
hydrolyzes the peptidyl-tRNA and releases the polypeptide from the ribosome, thus 
results in the termination of translation. 
1.3 Mt DNA diseases 
Mitochondrial diseases are clinically heterogeneous disorders that arise due to the 
dysfunction of the mitochondrial respiratory chain. They can be due to mutations of 
mitochondrial DNA (mtDNA). The mitochondrial respiratory chain is the essential final 
common pathway for aerobic metabolism, and tissues and organs that are highly 
dependent upon aerobic metabolism are preferentially involved in mitochondrial 
disorders (Wallace, 1999). 
1.4 MtDNA mutation and HCC 
Alterations in the expression of mtDNA-encoded polypeptides required for oxidative 
phosphorylation and cellular ATP generation may be a general characteristic of cancer 
cells. Mitochondrial DNA has been proposed to be involved in carcinogenesis because of 
high susceptibility to mutations and limited repair mechanisms in comparison to nuclear 
DNA. Since mtDNA lacks introns，it has been suggested that most mutations will occur 
in the coding sequences and the subsequent accumulation of mutations may lead to tumor 
formation. In solid tumors, elevated expression of mtDNA-encoded subunits of the 
mitochondrial electron respiratory chain may reflect mitochondrial adaptation to 
perturbations in cellular energy requirements. It is reported that mitochondrial genomic 
aberrations have been found in solid tumors of the breast, colon, stomach, liver, kidney, 
bladder, head/neck and lung as well as hematologic diseases such as leukemia, 
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myelodysplastic syndrome and lymphoma (Copeland et al, 2001). 
Nagahori K et al (1988) was the first to analyze mitochondrial DNA in hepatocellular 
carcinomas. Based on 3 points: 1) tumor proliferation is energy-dependent, 2) 
mitochondrial energy-production system is dominant for cell growth, and 3) liver 
mitochondria possess their own DNA and RNA synthesizing some of their own proteins 
including respiratory enzymes such as cytochrome oxidases. They examined a possible 
relationship between mutations of mtDNA and clinical status of cell proliferation in 10 
HCC patients who underwent liver resection. MtDNA of cancerous and the noncancerous 
portions of liver specimens were separated and then digested with Hinf I endonuclease. 
DNA filters made of the digested mt-DNA fragments on the agarose and polyacrylamide 
gel, were hybridized with a nick-translated 32P-labeled DNA fragments. In two cases, 
abnormal mt-DNA was detected. In the first case, the HCC tumor was the massive type 
“ that grew rapidly, invading the bile duct. One restriction fragment of 3.0 kb became 
larger by 60 bp in both the cancerous and non-cancerous tissue. In the second case, 
regarded as metachronous multicentric HCC, the second largest band of the 3.4 kb 
fragment of the cancerous tissue showed a wider range than that of the non-cancerous 
portion. The former change may indicate polymorphism but the latter indicates an 
occurrence of the mutation of mtDNA. 
Since hepatocellular carcinoma (HCC) is usually preceded by chronic inflammation 
caused by chronic viral infection, Nishikawa et al (2001) investigated the mutation of 
mitochondrial DNA (mtDNA) in the hepatocarcinogenesis that was associated with 
chronic hepatitis B or C vims infection. Compared with normal liver tissue, they 
observed that the frequency of mtDNA mutations was markedly increased in both 
non-cancerous and cancerous liver specimens from individuals with HCC. The mtDNA 
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sequences obtained from Ihe two cancerous tissue specimens contained 67 and 77 
mutations, half or more of which were also apparent in the mtDNA obtained from the 
paired non-cancerous tissue specimens. The findings imply that mtDNA mutations may 
have accumulated during the malignant transformation to HCC.In addition, the frequency 
of mtDNA mutations in HCC tissue was also greater than that described previously for 
other types of tumors. . 
Nomoto et al (2002) sought to identify mitochondrial mutations in HCC and assessed 
their use as clonal markers in multicentric hepatocellular carcinoma. Nineteen primary 
HCC tissue samples were analyzed for mutations within the mitochondrial displacement 
loop (D-loop). As a result, 13 of the 19 HCC cases (68%) were identified as having 
D-loop mitochondrial DNA (mtDNA) mutations in at least one tumor. In 3 of these 13 
cases, the same mutation was observed in multiple tumors, indicating monoclonal origin. 
“Remarkab ly , in 8 of the 13 mutated cases, they detected deletion/insertion mutations in 
the C-tract. In addition, they detected mutant mtDNA in 8 of the 10 tested paired plasma 
DNA samples using oligonucleotide mismatch ligation assay. And they concluded that 
mtDNA mutations within the D-loop control region are a frequent event in HCC, which 
provides a molecular tool for the determination of clonality. They applied the simple PCR 
fragment length detection assay and detected the identical C-tract deletion/insertion 
mutations in matched plasma DNA in 5 of these 6 cases with C-tract deletion/insertion 
mutations. In addition, they proposed that detection of tumor-specific mtDNA mutations 
in plasma DNA needs to be explored further for monitoring patients with primary HCC. 
Subsequently, Okochi 0 et al (2002) found thai mtDNA mutations could be detected in 
the serum. Somatic mutations in the D-loop region of tumor ml DNA were screened by 
direct sequencing in 50 patients, and then the paired serum samples were investigated 
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using mutation-specific mismatch ligation assay. True somatic mutations in the D-loop 
region were detected in 17 of 50 patients (34%). Subsequent screening for paired serum 
by mismatch ligation assay revealed that 5 of 15 paired serum samples (33%) contained 
the same mutations as primary tumors. 
More recently, the relationship between the multicentric occurrence of hepatocellular 
carcinoma (HCC) and the frequency of mutation of mitochondrial DNA (mtDNA) in the 
noncancerous hepatic tissue in patients infected with hepatitis C virus was investigated 
(Kubo S et al, 2003). Of the 48 patients, 33 had multicentric HCC were found to have 
three or more mtDNA mutations in the noncancerous hepatic tissue; Among the 15 
patients who had solitary HCCs, all had two or fewer mtDNA mutations in the 
noncancerous hepatic tissue. The high frequency of mtDNA mutations in noncancerous 
regions of the liver in patients with HCC suggests that the hepatocytes may readily 
undergo malignant transformation during the prolonged inflammation caused by chronic 
HCV infection. Thus, unusually high rates of mtDNA mutations might underlie the 
pathogenesis of multicentric HCCs and the hypercarcinogenic slate in patients infected 
with HCV. The mutations can also be found in the paired body fluids, namely, paired 
urine obtained from bladder cancer, saliva samples from head and neck cancer and 
bronchoalveolar lavage (BAIL) fluids from lung cancer (Fliss et al, 2000; Nomoto et al, 
2002; Okochi et al, 2002). It therefore suggests thai mlDNA has the potential to be used 
as a tumor maker for the early detection and diagnosis of cancers. 
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1.5 Aims of the study 
HCC is a leading cause of cancer deaths in the world, however, the precise molecular 
events leading to hepatic carcinogenesis are not well understood. Carcinogenesis is a 
multistep process involving the accumulation of genetic changes. Much attention has 
been directed to genetic events, such as activation of oncogenes, inactivation of tumor 
suppressor genes and defects of mismatch repair genes. Complex chromosomal 
instability has been identified as a major genomic alteration. 
However, there are still many aspects that cannot be explained by these genetic changes. 
Somatic cell hybrid studies have demonstrated that tumor-suppressive activity can be 
involved in the extra-chromosomal fractions (Jonasson and Harris, 1977; Sager, 1985). 
This implies that both nuclear and cytoplasmic elements are responsible for the steps of 
沪 carcinogenesis. Indeed, mitochondrial abnormalities have been observed in many human 
cancers, these include changes in structure, number, respiratory enzyme components and 
transport systems (Pedersen, 1978; Wilkie et al, 1983). In this regard, the finding of 
mutations and deletions in the mtDNA of tumor cells has focused the attention on these 
cytoplasmic organelles as concurrent factors in the progress of tumorigenesis (Shay and 
Werbin, 1987). . 
As above mentioned, mtDNA may serve as an informative marker to measure cellular 
oxidative stress and to trace the clonal lineage of tumorigenesis especially in the earlier 
stage of HCC, even before the lesion become clinically evident. However, mtDNA 
mutations are not currently a well-characterized marker ready for clinical use. There are 
only a limited number of small scales studies conducted, and mutations are 
mostlysporadic, and consistent finding has not been shown. There is thus a need to 
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identify mutation hotspot (s) in HCC by careful investigation of the mutational spectrum. 
The objectives of my research are: 
(1) First, by sequencing the whole mitochondrial genome, to investigate the rate and 
pattern of mutational changes in HCC and to determine mutational hotspots. 
(2) Using SSCP，PFLDA and sequencing to confirm the mutation hotspot(s) in a large 
series of HCC, with an aim to identify new tumor markers for the detection and diagnosis 
of HCC in clinical use. 
(3) By analysis of these mutations, to provide new insights into the role of mtDNA 








Ultrapure dNTP set 2'-deoxynucleosides 5'-triphosphate:d ATP, d CTP, d GTP and d TTP, 
Ammonium persulfate, and TEMED (N, N, N，，N, -tetramethylethylenediamine) were 
purchased from Amersham Pharmacia Biotech (Clearbrook, USA). 40% 
19:lAcrylamide/Bis (N，N’-methyulenebisacrylamide) Solution was from BIO-RAD 
(Hercules, CANADA). Almost all other chemicals were purchased from Sigma Chemical 
Company (Sigma, St. Louis, USA) if not specified. 
2.1.2 Primers 
Primers used in the research, including primers for the D-loop region of mt DNA, the five 
respiratory subunit genes and the whole mitochondrial genome are list in Table3-5. They 
were purchased from Invitrogen Life Technologies (Tokyo, Japan). 
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Table 3. Primers used in the whole genome section 
Fragment Primer Nucleotide Product Primer Sequence(5' to 3') 
code code positions(np) size (bp) 
1 IF 516-534 1286 CACACACACCGCTGCTAAC 
IR 1801-1782 TCATCTTTCCCTTGCGGTAC 
2 2F 1756-1776 1415 AATTGAAACCTGGCGCAATAG 
2R 3170-3161 GGGAAGGCGCTTTGTGAAG. 
NDl NDIF 3109-3127 609 TCAAATTCCTCCCTGTACG 
NDIR 3717-3700 GGCTACTGCTCGCAGTG 
3 3F 3536-3553 1334 TAGCTCTCACCATCGATC 
3R 4869-4852 GTCATGTGAGAAGAAGCA 
4 4F 4832-4849 1357 CACCCTCTGACATAAGG 
4R 6188-6171 GGGAAACGCCATATCGGG 
5 5F 6115-6134 1501 TACCCATCATAATCGGAGGC 
5R 7615-7597 TTGTAGACCTACTTGCGC 
6 COIIF 7526-7550 1116 AGAAAAACCATTTCATAACTTTGTC 
6R 8641-8621 TGATGAGATATTTGGAGGTGG 
7 7F 8563-8581 1305 ACAATCCTAGGCCTACCCG 
’ 7R 9867-9848 GGATGAAGCAGATAGTGAGG 
8 8F 9821-9841 1212 ACTTCACGTCATTATTGGCTC 
8R 11032-11013 TCGTGATAGTGGTTCACTGG 
9 9F 10985-11004 1377 ACAATCATGGCAAGCCAACG 
9R 12361-12341 TGGTTATAGTAGTGTGCATGG 
ND5 ND5F 12281-12300 674 C A G C T A T C C A T T G G T C T T A G 
ND5R 13555-13529 AGGCGTTTGTGTATGATATGTTTGCG 
10 iOF 13504-13520 1425 TTCTACTCCAAAGACCACAT 
lOR 14928-14911 GTTGAGGC GTATGGTGAG 
CytB CytBF 14715-14736 1211 ACCATCGTTGTATTTCAACTAC 
CytBR 15 904-15925 GTTTAC AAGACTGGTGTATTAG 
D-loop DF 15879-15900 1266 AATGGGCCTGTCCTTGTAGTAT 
D346R 576-554 TGTGGGGGGTGTCTTTGGGGTTT 
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Table 4. Primers and conditions for coding region analysis (From Habano et al, 
1999). 
Region Annealing Primer sequence 
Gene (nt.)^ ( � C ) Digestion ( 5 � 3 � 
NDl 3109-3717 55 Mspl, TCAAATTCCTCCCTGTACG 
Alul 
GGCTACTGCTCGCAGTG 
c o i l 7526-8328 60 Mbol, AGAAAAACCATTTCATAACTTTGTC 
CTTAAAAGGTTAATGCTAAGTTAGC 
ND4 10452-11542 64 Alul GATAATCATATTTACCAAATGCC 
GAAGGGGTAGGCTATGTGTT 
ND5 12281-13555 60 Tru9I, CAGCTATCCATTGGTCTTAG 
StuI 
AGGCGTTTGTGTATGATATGTTTGCG 
Cytb 14715-15925 60 Mbol ACCATCGTTGTATTTCAACTAC 
GTTTACAAGACTGGTGTATTAG 
WUWUTJWUWUVWWWVVVVWuWuWUWVVVUWWWVVVWWVLfWLfV^WWWWWVWWWVVWWWVWWWVWrt�Wi»i1�*»*i��I��-i-i-i��v>yiVV»*i���-i*»VVi«t"V-�����—>-"^*"*>-*"�''����������������-^"*^-^�-^���"*^���"^�">-»"^— 
1 Nucleotide (nt.) numbers as determined by Anderson et al (1981). For each primer, 
the first oligonucleotide represents the forward primer, and the second corresponds to 
the reverse primer. All PGR products were obtained by 35 cycles of amplification. 
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Table 5.Primers for the D310 region in the D-loop (Montserrat, et a l , 2001) 
Primer code Necleotide position (np) Primer Sequence (5，to 3，） 
D31 OF 250-266 AC AATTG AATGTCTGCACAGCCACTT 
D310R 349-327 GGCAGAGATGTGTTTAAGTGCTG 
D346R 576-554 TGTGGGGGGTGTCTTTGGGG 
2.1.3 Enzymes 
Restriction enzymes, Alul, Mbol, Mspl, and Tru9I were purchased from New England 
BioLabs (NE BioLabs，USA) while StuI from Promega (Promega, Madison, USA). DNA 
‘ p o l y m e r a s e I used in this study was Ampli Taq Gold''^ DNA polymerase, while the one 
used for sequencing reaction was from BigDye"^ Termination cycle-sequencing v.3. Both 
of them were purchased from Applied Biosystems (ABI, Branchburg, New Jersey, USA). 
2.1.4 Cell line 
The only hepatoma cell line Hep3B was purchased from American Type Culture 
Collection (ATCC), provided by the Department of Clinical Oncology. Its DNA was 
extracted and used in this study to investigate the mtDNA mutations. Culture media 
DMEM contained 10% heat inactivated fetal calf serum (Invitrogen life technologies 
USA), lOOU/ml of penicillin and streptomycin, and the cells were maintained in an 
incubator set at 3 7 � C with 95% air and 5% CO2. 
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2.1.5 Collection of specimens 
Materials from a total of 55 Chinese patients, with histological confirmed HCC from 
Hong Kong were used in this research. Tissues were surgically resected, at the Prince of 
Wales Hospital, Faculty of Medicine, the Chinese University of Hong Kong during the 
year 2001-2002. Informed consent was obtained. 
Fresh tissues, from both primary tumors and adjacent non-tumor liver, each consisting of 
fragments varying between 0.5 and 1 cm in diameter, were collected. Each of the samples 
was divided into two parts: one part was quickly frozen in liquid nitrogen and stored at 
-80°C until DNA isolation, while the other part was processed for histopathological 
examination for the confirmation of diagnosis as well as to ensure that more than 70% of 
. t h e cells from resected tumor tissues were tumor cells. Each fragment was carefully 
labeled, and the frozen tissues and histological sections were matched. The non-tumor 
tissues were confirmed histologically. Tissues of 50mg each were then used for DNA 
extraction. 
Peripheral Blood Mononuclear Cells (PBMCs) from 50 normal subjects and 17 HCC 
patients were also collected and stored at -70°C untill they were used for DNA isolation. 
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2.2 Methodology 
DNA was extracted from tissues, PBMCs and a cell line (Hep3B) by detergent lysis and 
proteinase K digestion (20mg/ml). The regions to be studied were PCR-amplified by 
mtDNA-specific primer pairs. To investigate the mutation pattern and distribution of 
mtDNA, whole mtDNA genome from 4 HCC patients and cell line Hep3B were directly 
sequenced. After ahotspot (D310) and other potential hotspots being identified, the D310 
region in the tumor and paire adjacent non-tumorous tissue from 55 HCC cases were 
amplified by PGR and subjected to PCR fragments length detection assay (PFLDA) to 
screen the alterations in this region and then identified by direct sequencing. Besides, this 
region was further investigated in PBMCs from 50 normal subjects and 17 HCC patients. 
To study the alterations in the coding region of mt DNA and, five coding genes of 
mitochondrial respiratory subunits were amplified and screened for the mutations by 
. S i n g l e - s t r a n d Conformational Polymorphism (SSCP) after digested by proper restriction 
enzyme, five cases of each gene showed mobility shifts in SSCP were subsequently 
sequenced to confirm the mutation. 
2.2.1 DNA extraction from tissues, cell line and PBMCs 
2.2.1.1 DNA extraction from HCC tissues 
The total genomic DNA was extracted from the liver tissues according to the method by 
Brechot (1981) with slight modifications. One hundred mg of tissue specimens were 
pulverized to the powder packaged in two layer of aluminum foil after immediately taken 
from liquid nitrogen. Tissue sample powder 0.1 g was then transferred to 1ml digestion 
buffer (20mM Tris-HCl PH=7.8, 2mM EDTA PH= 8.0，0.1% SDS). The liquid was 
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gently mixed with 50 ul proteinase K (20 mg/ml) and digested at 58°C overnight (16h). 
The DNA solution was extracted once with a buffer-saturated solution of 1ml phenol: 
chloral: isopropanol (25:24:1 ;v/v/v) by centrifugation at 12,000 rpm for 5 min at room 
temperature. The supernatant was aspirated and then the DNA was precipitated by 
addinglOOul sodium acetate (NaAc 3M) and 2ml absolute ethanol. The DNA was then 
precipitate at -20�C for 2hours. After centrifugation at 12,000 g for 10 minutes at 4�C， 
the supernatant was removed and restored, followed by washing with 1:1 75% ethanol 
(2/3 tube volume). RNA present was digested with lOOmg/nl of DNase-free RNase A for 
1 hour at 37�C. The enzyme was inactivated by incubating with 0.5% SDS together with 
proteinase K at lOmg/ml for 1 hour at 55"C. Again, the DNA precipitate was pelleted by 
centrifuging at 12,000 g for 2 minutes at 4�C. After drying at room temperature for 15min, 
DNA was re-dissolved in lOOul ofTE. The samples were stored a t - 2 0 � C until for further 
use. Special care was taken to avoid cross-contamination among the sample. 
The quality and quantity of DNA were determined by 0.8% agarose gel electrophoresis. 
The presence of a high molecular weight band indicated that the quality of the extracted 
DNA was suitable for research. The yield and purity of the DNA were determined by 
measuring absorbance of the diluted DNA at 260nm, 280nm, and 330nm using a 
spectrophotometer (GeneQuant RNA/DNA, Pharmacia, Sweden). 
Purity Check: A ratio of (A260-A330): (A280-A330) between 1.8 and 2.0 is an 
acceptable parameter for DNA. A ratio below this range indicated that a small amount of 
protein remains in the sample. A ratio above this range implies the presence of RNA 
remaining in the sample. 
DNA concentration (mg/ml) =(A260-A330)xDFx 50 
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A260, A280 and A330 are the absorbance readings at 260nm, 280nm and 330nm 
respectively and DF is the dilution factor. One absorbance unit al 260 nm corresponds to 
a concentration of 50mg/ml of DNA. 
2.2.1.2 DNA extraction from cell line Hep3B 
Total DNA was extracted from the cell line Hep3B using phenol/chloroform (Maniatis et 
al, 1989). To extract DNA from the cell line, the cell monolayers were washed twice with 
ice-cold Tris-buffered saline (TBS). The cells were scraped into approximately 0.5 ml of 
TBS using a rubber policeman and then the cell suspension was transferred to a 
centrifuge tube and stored on ice. The cells were recovered by centrifugation at 1500g for 
10 minutes at 4 °C, and then resuspended in 5-10 volumes of ice-cold TBS. The cells 
, were resuspended in TE (lOmM Tris-HCl pH7.5, ImM EDTA) at a concentration of 
5 x 1 c e l l s / m l , and then 10ml of extraction buffer was mixed with 1 ml of the cell 
suspension. The solution was incubated for 1 hour al 37 and then proteinase K was 
added to a final concentration of 1 OOmg/ml. After incubation overnight at 55 the 
solution was cooled and the cellular DNA was extracted by mixing with 10ml of ice-cold 
solution of phenol/chlorofornVisoamyl alcohol (25:24:1; v/v/v) for 10 minutes. The 
mixture was then spun at 4000 rpm for 20 minutes at room temperature. 
The upper aqueous phase was collected. DNA was precipitated by mixing with one-tenth 
� of the volume of 3M sodium acetate (pH 5.2) and two volumes of absolute ice-cold 
ethanol. The DNA was then pelleted at 4000 rpm for 20 minutes, washed once with 70% 
ethanol and finally dissolved in 5 ml of TE (pH 7.5). RNA present was digested with 
1 OOmg/ml RNase A. The DNA was again extracted with phenol/chloroform/isoamyl 
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alcohol solution, precipitated with ethanol and dissolved in 500 ul TE. After checking 
and measuring the quality and quantity of DNA, the samples were stored at -20°C. 
2.2.1.3 DNA extraction from PBMCs 
2.2.1.3.1 Preparation of PBMCs 
Peripheral Blood Mononuclear Cells (PBMCs) from 50 normal subjects and 17 HCC 
patients were also collected and stored at - 70 °C until they were used for DNA 
isolation. To separate PBMCs, first solution A and B were prepared, then balanced salt 
solution (BSS) was made by mixing 1 volume solution A with 9 volume solution B 
(0.14M NaCl). One gram Anhydrous D-glucose，7.4 mg CaCbSl^bO, 199.2 mg 
MgCl2 6H20, 402.6 mg KCl and 17.565 g Tris were dissolved to IL and then pH was 
• adjusted to 7.6 to get solution A. After 6 ml of peripheral blood from each subject were 
freshly collected and spun at 200 rpm for 5 minutes, the supernatant (plasma) were then 
pipetted out, and the blood pellet was mixed with 3 ml BSS. Then the mixture was gently 
and slowly overlayed to 3 ml Ficoll-Paque (Pharmacia Biotech, USA) followed by 
centrifugation at 400 g for half an hour. Subsequently, the interface (PBMC layer) was 
transferred to a fresh 15 ml falcon tube and washed with 6 ml BSS. After centrifugation 
at 2000 rpm for 8 minutes, the supernatant was removed and the cell pellet was 
resuspended and washed with 2 ml IxPBS (Phosphate-buffered saline, 1.4 mM NaCl, 
0.01 M Na2HP04, 2.0 mM KH2P04and pH 7.4). Finally, the PBMC pellet were collected 
and ready for DNA extraction by brief centrifugation. 
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2.2.1.3.2 PBMC DNA extraction 
The DNA of PBMCs was extracted by standard phenol/chloroform methods. After the 
PBMCs were lysed by lOOmg/ml proteinase K, the solution was subjected to 
phenol/chloroform extraction followed by sodium acetate precipitation, exactly the same 
as mentioned in section 2.2.1.2. 
2.2.2 Detection of mt whole genome mutation by direct sequencing 
2.2.2.1 Design of mtDNA primers 
Primers used for amplification of different regions of the mtDNA genome were chosen 
from published Cambridge reference sequence or by analysis of the genome using a 
- software called Primer Finder in the website of the University of Adelaide 
(http://www.microbiology.adelaide.edu.au/leam/). The following oligonucleotide primers 
were used for PCR amplification and sequence analysis and were purchased from 
Invitrogen USA. (Table 3, 4, 5). The oligonucletides were synthesized on an automated 
DNA synthesizer, using phosphoramidite chemistry. They were deprotected, cleaved and 
purified by the standard protocol. 
2.2.2.2 PCR amplification of the whole mt genome 
Amplification of all mtDNA fragments was carried out according to the method 
described by Taylor et al (2001). A series of overlapping primer pairs (Table 3) were 
designed to amplify the human mitochondrial genome in 14 fragments with a length 
ranging from 674 bp to 1501 bp. Almost all PCR amplifications except those containing 
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D-loop were performed in a20 {i\volume containing Ix PCR buffer (10 mM Tris - HCl, 
pH 8.8，3.0 mM MgC12), 0.2 mM dNTPs, 0.2 / / M primers, 1 U AmpliTaq Gold DNA 
polymerase (Applied Biosystems) and 1 (i I (25ng) of tissue DNA. Reaction were 
carried out under the following conditions: 95 °C for 10 min, 35 cycles of 94 °C for 30 
seconds, 60 °C for 1 minute (62 °C for fragment 7) and 72 °C for 2 min, and the final 
extension proceeded for 7 min. In all of the PCR reactions, reaction mixtures without any 
template DNA were recruited as negative control. The capacity of these primer pairs to 
amplify nucleus-embedded mtDNA pseudogenes were ruled out for each of the products 
of this reaction was exactly the same size as expected. All PCR amplification were 
performed using a GeneAmp® PCR system 9700 PCR machine (Applied Biosystems, 
USA). 
2.2.2.3 Direct sequencing of the whole mt genome 
2.2.2.3.1 Primer used in sequencing 
Primers used in the PCR amplification of the whole genome fragments were also used in 
the direct sequencing. Both the forward and reverse primers were used to cover the whole 
length of the fragments except for NDl genes. Dye Terminator Cycle Sequencing were 
performed using an ABI PRISM® BigDye™ Terminators v 3.0 Cycle Sequencing Kit 
(Foster City, USA). 
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2.2.2.3.2 Purification of the PCR products of the whole mt genome 
All PCR products were undergone purification using the QIAquick PCR purification kit 
(QIAGEN, Germany) before sequencing reaction. The QIAquick system used a simple 
bind-wash-elute procedure. 20ul PCR products were mixed with lOOul binding buffer 
Buffer PB and applied to the QIAquick spin column where DNA bound to the silica-gel 
membrane. These were then centrifuged for 30 seconds at 13,000 rpm. Impurities were 
washed away by centrifugation for 1 minute at 13,000 rpm after adding Buffer PE, and 
pure DNA was eluted in 30ul low-salt elulion buffer, Buffer EB (lOmM Tris-Cl, pH8.5), 
this was then ready for use in subsequent cycle sequencing. 
2.2.2.3.3 Dye terminator cycle sequencing reaction 
An ABI PRISM® BigDye™ Terminators v3.0 Cycle Sequencing Kit was used to 
sequence the purified PCR amplification products. Cycle sequencing reaction was carried 
out according to the manufacturer's direction with some modifications. The total volume 
of the reaction was reduced from 20ul to 5ul proportionally to economize the procedure 
according to the following formula: 2.0 ul BigDye Terminator v 3.0 polymerase, 0.25 ul 
3.3 uM primer, 0.75 ul Milli-Q H2O and 2.0 ul (5-10 ng) template DNA. For each 
reaction, these components, were added to a 0.2 ml tube. Reaction mixture was overlaid 
with 8 ul of light mineral oil. Then, cycling sequencing was completed on the GeneAmp® 
PCR system 9700 PCR machine using the following temperature profile: 95 °C for 10 
seconds for activation, then 35 cycles of denaturation at 95 °C for 10 seconds, annealing 
at 52 °C for 10 seconds and extension at 60 °C for 3 minutes, followed by a final 
extension at 60 °C for 5 minutes. 
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2.2.2.3.4 Purification of extension products 
Prior to analysis on ABI automated sequencer, the excess dye-labelled 
dideoxynucleotides were removed from sequencing reactions by spin columns containing 
Sephadex G-50 DNA Grade F. Columns were prepared by dissolving 1 g of Sephadex 
G-50 powder in 11-12 ml of sterilized ddHsO. After equilibration at room temperature for 
2 hours, 0.55 ml of resin was pipetted to a microspin column. Then, the column was 
pre-spinned for 2 min at 730 g in a microcentrifuge. The columns were ready for use. The 
cycle sequencing reaction product was diluted to 20 ul by adding 15 ul Milli-Q H2O and 
then spun briefly. The entire 20-ul products was applied to the centre of the angled 
surface of the resin bed carefully without resin disturbing and any of the samples flowing 
around the sides of the bed. The column was spun for 1 minute at 2000 x g. Purified 
sample was collected in the bottom of the support tube and mixed with 15 ul of Hi-Di 
, formamide. After being dried in a speed vac for at least 15 minutes, samples were 
denatured by heating for 5 minutes al 95°C and placed on ice immediately. Finally, 
samples were sequenced on an automated sequencer named ABI PRISM® 3100 Genetic 
Analyzer (Applied Biosystems, USA) according to the manufacturer's instructions. All 
the sequencing data were then analyzed using software in the website of 
http://www.microbiology. adelaide.edu.au/leam/ and http://www.ncbi.nlm.nih.gov/blast/ 
for DNA analysis and http://tw.expasv.org/ for the analysis of the functional changes of 
the detected DNA alterations and mutations. 
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2.2.3 Detection of mtDNA control region mutation 
2.2.3.1 PCR amplification of D310 in the mtDNA control region 
Between 10 and 100 ng of total DNA were used to amplify the D310 repeat from 55 
cases of paired normal and tumor samples and PBMCs from 40 normal subjects and HCC 
patients. The sequence for the forward primer was D310F: 5'-ACAATT GAATGTCTGC 
ACA GCC ACTT-3' and for the reverse primer D310R: 5'-GGCAGAGATGTG 
TTTAAG TGCTG-3' (shown in Table 5). The concentrations of the reagents used in the 
PCR were as described previously in section 2.2.2.2. After an initial denaturalization step 
at 95° C for 10 min, samples were cycled 35 times as follow: 95° C for 30 s, 60° C for 
30 s, and 7 2 � C for 1 min. The final extension was al 72°C for 4 min. After purification 
(see section 2.2.2.3.2) with a QIAquick PCR purification kit (QIAGEN，Hilden, 
. G e r m a n y ) , One- fourth of the PCR product was loaded in the 6% denaturing 
polyacrylamide gel, as described below. 
2.2.3.2 Screening D310 mutation by PCR fragment length detection assay (PFLDA) 
2.2.3.2.1 Making 8% denatured gel mixture 
The methods below were used, and yielded sufficient for a standard 40 x 40 cm x 0.4 mm 
gel. It was -essential to use only ultrapure reagents in preparing DNA denatured gels. 
Twelve ml 40% acrylamide/Bis-acrylamide solution (Bio-Rad laboratories, USA)，and 
6.0ml 5 X TBE (Tris-borate-EDTA)，and 28.8 gram USB ™ ultrapure urea (United State 
Biochemical, Cleveland, Germany) together with 20 ml double distilled water (ddHzO) 
were mixed and then the total volume was adjusted to 60 ml by adding ddHzO. After the 
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mixed solution was filtered through Whatman 3 MM filter or equivalent. 200 ul frozen 
aliquot of 10 % ammonium persulfate (AP) and 50 ul TEMED were immediately added 
to the mixture. The gel mixture was then ready to pour out as gel. 
2.2.3.2.2 Setting up and pouring the denatured gel 
First, glass plate sandwich of the gel mould was set up by the following procedure: The 
long plates was placed on the table with the inside surfaces of the plates facing up. Then 
two plastic spacer strips were wiped with ethanol and placed one along each of the long 
edges of the long plate with the rubber cushions at the top and facing up. The short 
plate was placed directly on top with the inside surface down and the plates and spacers 
were lined up precisely with the rubber cushions of the spacer strips fitting snugly against 
the top edge of the short plate. Three sides of glass plate sandwich were sealed with a S2 
. c a s t i n g boot (Life Technologies, USA). The sandwich was sealed tightly. Then, gel 
mould were picked up and tilted up at 45 degree angle or greater with table and slightly 
to one side. Sixty ml of polymerizing mixture was slowly and smoothly squirted into the 
space between the plates at a point near the low side edge, avoiding the formation of 
bubbles or spilling. When the fluid was about three inches from reaching the top of the 
mould, squirting was stopped and the mould was placed, long plate down, flat on the 
empty pipette racks again. The fluid came up to fill the entire gap between the plates. 
Remainder of fluid was squirted back into bottom of the 150 ml beaker so that 
polymerization could be monitored. The two plastic combs slided in between the plates 
into the gel mix with the flat sides in (teeth out). Flat surfaces of combs formed an even 
line, about half-centimeter deep into the gel. Then, one clamp was placed along the top of 
gel mould. After leaving on empty pipette racks for a minimum of an hour (up to 
overnight), the gel was ready for use. 
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2.2.3.2.4 Preparing and loading the PCR products 
The loading formamide dye mix was prepared in advance in the following formula: 
formamide 10 ml, xylene cyanol 10 mg, bromophenol blue lOmg and 0.5 M EDTA 200 
ul. Five ul of the purified PCR products were mixed with 15 ul of the loading and 
denatured at 95 ()C for 5 to 10 minutes. Then, the sample tube was immediately plunged 
into ice. Subsequently, 5 ul of each sample was loaded on the denatured gel with a 
micropipettor. Non-denatured samples, which remain double-stranded, were also 
recruited as controls. 
2.2.3.2.5 Electrophoresis 
The denatured gel was utilized to detect base insertion/deletions, for the samples were 
. .denatured and kept denatured during the electrophoresis. It was because high 
concentration of urea (7 to 8 molar) in the gels prevented folding of the molecules and 
formation of secondary structures by hydrogen bonding that would alter the mobility of 
the molecule, and the gels are run at higher temperature (about 50�C)，which also prevent 
H bond formation. So the migration mobility of the PCR amplified molecules was only 
influenced by the strand length. Even a single base difference can be detected if the gel 
was long enough. Just before the samples were loaded, the denatured gel was pre-run in 
0.5 TBE buffer at 30 w for 30-60 minutes until a temperature of 5 0 - 6 0 � C was reached. 
Then, electrophoresis was performed at 30 vv until the last band of bromophenol blue dye 
reached the bottom of the gel. This took approximately 2 .5 to 3 hours. 
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2.2.3.2.6 Gel fixing, silver staining and color development 
Fixing, staining and developing solutions were freshly prepared while gel was running. 
Formaldehyde, silver nitrate and sodium thiosulfate were added to solutions immediately 
prior to use. One litre of 10 % acetic acid was made for fixing the gel by diluting 100 ml 
100% acetic acid glacial (Merck KgaA, Germany) with double distilled water (ddHzO). 
To prepare staining solution, 1 g silver nitrate and 3 ml 37% formaldehyde were 
combined with 1 L ddHsO. And 30 g sodium carbonate, 3 ml 37% formaldehyde and 1 L 
chilled ddHzO were mixed to prepare developing solution, then it was chilled to 4-10�C 
and just shortly before the developing, 2 mg sodium thiosulfate was added to the 
developing solution. After carefully removing the gel assemble from a rig with a spatula, 
the gel was subjected to fixing with gentle agitation for about 30 minutes in 1 liter of 
10% glacial acetic acid, until tracking dye completely disappeared. The gel was rinsed 3 
. t i m e s for 2 minutes each with distilled water with gentle agitation, it was then ready for 
staining. In the same way, gel was placed in the 1% silver nitrate solution and was gently 
agitated for 30 minutes. Again, the gel was quickly rinsed with distilled water for 5 
seconds and then transferred to 800 ml of chilled developing solution with sodium 
thiosulfate; gentle agitation was applied until the bands first became visible in roughly 5 
minutes. I then decanted the.used developer, added the remaining chilled developer and 
continued to gently agitate until the bands have reached the desired intensity. To 
terminate the developing reaction, an equal volume of chilled, fix/stop solution was 
added and incubated with gentle shaking for 5 minutes. As soon as the bubbling stopped, 
gel was rinsed thoroughly in ddHiO During the whole procedure, the gel remained 
attached to the plate coated with bind silane. Finally the gel was covered with a sheet of 
Whatman filter paper, stuck to it and was scraped off the plate, then the filter paper was 
dried by speed vacuum at 60°C for 30 minutes and stored for permanent record. The 
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bands mobility shifts between the paired non-tumor tissue and tumor tissue were then 
investigated. Those that moved faster were considered to harbor a deletion and those that 
moved slower were considered to undergo an insertion. All the samples with band 
migration shift was then selected and was subjected to direct sequencing for the 
confirmation of deletion/insertion. 
This application of silver staining was a very sensitive but unstable method. Any minor 
mistakes would yield a poor result. All the water used should be distilled water. It was 
important to keep all the solution pre-chilled to 4-10�C to minimize brown background. It 
was worth noticing that the rinsing step after staining was crucial, longer rinses resulted 
in weaker signal but shorter rinses led to a dark background, it was very difficult to 
conduct this properly in the real practice,but the optimal duration was 5 seconds. If the 
rinse went too long, staining steps should be repeated. 
2.2.3.3 Direct sequencing of D310 in the mtDNA control region 
A 346-bp fragment containing the D31() repeat was PCR amplified from lymphocyte 
DNA of eight patients. The sequence of the primers was: forward D310F, 
5'-ACAATTGAATGTCTGCACAGCCACTT-3'; and reverse D346R, 5'-TGTGGG 
GGGTG TCTTTGGGG-3'. The PCR products were purified with a QIAquick PCR 
purification kit (QIAGEN, Germany) before sequencing reaction (see section 2.2.2.3.2). 
To rule out possible mistakes in the PCR reaction, the assay was repeated for all 
normal-tumor pairs that showed D31() alterations in the tumor DNA. DNA was purified 
and then sequenced (see section 2.2.2.3.4) on an ABI PRISM® 3100 Genetic Analyzer 
(Applied Biosystems, Foster City, USA) using the forward primer 5_-GGCAGA GATGT 
GTTTAAGTGCTG-3'. 
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2.2.4 Detection of mt DNA coding region mutation 
Mutations of the 5 mitochondrial genes encoding NDl , ND4, ND5, cytochrome b (Cyt B) 
and cytochrome c oxidase subunit II (COII) were independently screened by non-RI 
PCR-SSCP analysis (Habano etal, 1999). 
2.2.4.1 PCR amplification of the 5 respiratory chain subunit genes 
For the amplification, 200 ng of total cellular DNA from carcinoma specimens was used 
in a 20 IM PCR mixture as mentioned before (section 2.2.2.2) on a 9700 GeneAmp PCR 
system (ABI, USA) under the following conditions: initial denaturation of 10 min at 
95°C, followed by 35 cycles of 30 seconds al 94 °C，50 seconds at 5 5 � C for NDl, 60 °C 
for COII, CytB, ND5 and 62 °C for ND4’ 2 minutes al 7 2 � C , and a final extension of 
. 7 2 ° C for 7 minutes. The resulting products and DNA molecular markers (200-bp 2000 
plus ladder, Takara Shuzo) were separated by electrophoresis on a 1.3% agarose gel (150 
xl50 mm) and visualized by ethidium bromide staining to make sure the size of each 
genes was exactly as expected and the possibility of pseudogenes was ruled out. 
2.2.4.2 Restriction enzyme digestion of 5 genes in mtDNA coding region 
An 10 ul aliquot of each PCR products was digested by 5 units of restriction enzymes, 
Alul，Mbol, Mspl, StuI and Tru9I accordingly (as shown in Table 3) for 2 hr at 37 °C. In 
addition, products of ND5 were digested by 5 U Trul al 6 5 � C overnight after incubation 
with 5 U StuI and 2 ng BSA. Appropriate digestion buffers were used according to 
manufactures' instruction. The resulting digestion products and DNA molecular markers 
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(200-bp ladder, Takara Shuzo) were separated by electrophoresis on a 1.3% agarose gel 
and visualized by ethidium bromide staining with expected number of fragments and 
size. 
2.2.4.3 Screening of mtDNA coding region mutation by SSCP 
Single-Strand Conformation Polymorphism analysis was orginally described by Orita et 
fl/ (1989). The general idea was to take a small PCR product (a.k.a. amplicon), denature it, 
and electrophorese it through a non-denaturing polyacrylamide gel. Thus, as the PCR 
product moved into and through the gel (and away from the denaturant), it would regain 
secondary structure that was sequence-dependent. The mobility of the single-stranded 
PCR products would depend upon their secondary structure. Therefore, PCR products 
that contained substitution sequence differences as well as insertions and deletions would 
, h a v e different motilities. All the procedures were very similar to those of PFLDA apart 
from the use of natured gels. 
2.2.4.3.1 Making 6% 49:1 acrylamide/Bis SSCP gel mixture 
The methods described below were very similar to those of section 2.2.3.2.1, and were 
sufficient for a standard 40 x 40 cm x 0.4 mm gel. First, 250 ml 40% (49:1) acrymide: 
Bis-acrymide was prepared by mixing 60 g acrylamide powder with 40% acrylamide 
/Bis-acrylamide solution (Bio-Rad laboratories, USA) and 90 ml double distilled water 
(ddH20). The solution was stored at 4 � C for the following SSCP gel making. Then the 
gel solution was made by mixing 9ml 40% 49:1 acrylamide/Bis solution, 6.0ml 5 X TBE 
buffer，and 45ml ddHaO. The total volume was then adjusted to 60ml by adding ddHzO. 
320ul frozen aliquot of 10% ammonium persulfate (APS) and 32 ul TEMED were 
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immediately added to the mixture. The gel mixture was then ready to be poured out as a 
gel. 
2.2.4.3.2 Setting up the SSCP gel, loading sample, fixing, staining and developing of 
the gel. 
The procedures were similar to those of the denatured gel except for some modifications. 
The difference in procedures was mainly in the step of electrophoresis. The SSCP gel 
electrophoresis were under two conditions, namely at room temperature and at 4 °C, to 
ensure that any conformational difference could be detected even if there was only minor 
difference as little as a single base between non-lumorous and tumorous sequences. The 
electrophoresis was performed under a constant voltage of 300 v instead of constant 
wattage in PFLDA. The running process usually lasted for 12-13 hours at room 
, t e m p e r a t u r e and 15-17 hours at 4° C, until the band of bromophenol blue dye reached the 
bottom of the gel. 
2.2.4.4 Sequencing conformation of the mtDNA coding region mutation 
Five samples of each of the 5 coding genes, which showed mobility shift in SSCP, were 
selected randomly to be sequenced, thereby to identify and confirm the alterations. The 
sequence obtained were then compared with the Cambridge reference sequence in a 




2.2.5.1 The Chi-Square test 
Chi-squire test was used to compare various kinds of D310 C-tract polymorphism types. 
In this study, samples were categorized into 4 groups: the group of HCC tissue, 
non-tumorous tissue, and PBMCs of normal subjects and HCC patients. The D310 
polymorphism patterns were compared, based on the null hypothesis that the patterns 
(proportions) in each group were the same, namely, the proportion of samples whose 
c-tract was 7-C and those whose C-tract was not 7-C were the same. The tests were then 
performed with a significant P value set as 0.05. If the P value calculated was less than 
0.05, the null hypothesis was rejected, i.e. the pattern was statistically different. 
2.2.5.2 The Friedman test 
This was utilized to compare the mutation patterns between the D310 region and 5 coding 
genes in each case to assess if they had the same mutation distribution with a significant 
P value set as 0.05. 
2.2.5.3 Wilcoxon Signed Ranks Test 
After differences in the distribution of the mutations were detected, the specific 
differences were further analyzed. Therefore, the tests for two related regions from the 






3.1 Detection mtDNA whole genome mutation 
3.1.1 Identification of mtDNA whole genome by direct sequencing 
In an attempt to get an over-all impression on the alteration/mutation spectrum of 
mtDNA in HCC, mtDNA from one human HCC cell line, Hep3B, and four HCC tissues 
were analyzed by directly sequencing of their whole genome. The sequences obtained 
were compared with those recorded in the extensive mitochondrial databank 
(http://www.gen.emorv.edu/mitomap.html), which is also called the Cambridge reference 
sequence, to determine the alteration was related to polymorphism or mutation. Table 6 
summarizes the result of this analysis. 
The data showed that there were frequent mutations located in the mtDNA. There were a 
.. total of 150 sequence variants found in the five whole mitochondrial genomes. Among 
the 150 alterations, 42 (26.8%) of Ihem were located in the mtDNA D-loop region and 
the other 108 (73.2%) were located in the coding region. Forty-six out of the 150 
alterations were identified as mutations, including 38 new mutations, which had never 
been reported previously. The remaining 104 alterations were regarded as polymorphisms. 
In most cases (38 of 46 mutations), the mutations were sporadic apart from A8452T, 
located in the tRNA synthase, which was found to be a consistent mutation in three out of 
five cases (60%) in two HCC tissues (case 111 and easel 15) and the Hep3B cell line. 
And consistent with previous observations (Polyak et al, 1998; Fliss et al, 2000; Yeh 
e/ al, 2000; Nishikawa et al, 2001), most of the mutations detected in the present study 
were homoplasmic. One hundred and twenty-nine of the 150 alterations (86%) were A 
- G or C-T transitions. However, mtDNA large deletions were not observed in HCC. 
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Among these variants, 31 alterations were predicted to alter the amino acid sequence of 
the encoded protein, 55 variants in the protein coding regions were silent, 16 variants 
were predicted to affect rRNA (15 variants) or tRNA genes (one variant), and eight were 
predicted to affect ATP synthase (four for ATPaseS, and four for ATPase6) as well as two 
frameshifts being predicted to affect CytB and ND5 genes. In addition, only one mutation, 
a C15978T was identified lo influence the mitochondrial membrane attachment site 
(MTATT) in the cell line Hep3B (as shown in Table 6). 
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Table 6. mt DNA whole genome alterations in 4 HCC tissues and the Hep3B cell line. 
Case No. Nucleotide position and Change Amino acid change Location 
Hep3B A73G � D-loop 
309 ins C � D-loop 
316 ins C ~ D-loop 
T489C � D-loop • 
T16086C ~ D-loop 
C16104T � D-loop 
A16172T � D-bop 
C16223T � D-loop 
C16277T � D-loop 
A16292G ~ D-loop 
C16293T ~ D-loop 
T16311C � D-loop 
C16360T ~ D-loop 
T16519C ~ D-loop 
” G769A � RNRl 
‘ T825A ~ RNRl 
G1018A � RNRl 
2395del A* ~ RNR2 
A2706G � RNR2 
G2758A ~ RNR2 
T2885C � RNR2 
T3096C* � RNR2 
C3594T • syn NDl 
G3666A syn NDl 
A4104G* . syn NDl 
A5951G* syn COI 
T6071C* syn COI 
G6179A* syn COI 
T6221A* syn COI 
T6297C* syn COI 
A6353G* syn COI 
T662QC* syn COI 
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Table 6. (Continued) 
Case Nucleotide position and Change Amino acid change Location 
'C7028T ^ COI 
A7146T syn COI 
C7256T syn COI 
T7389C Y-H COI 
G7521A � MTDD 
G7805A* V-I c o n 
A7844G* T-A COII 
G8027A A-T COII 
A8452T** L-F ATP8 
C8468T syn ATP8 
A9067G** M-V ATP6 
G8860A A-T ATP6 
A10398G T-A ND3 
G10586A syn ND4L 
G10688A syn ND4L 
„ T10810C syn ND4 
T10873C syn ND4 
C11302T** syn ND4 
G11719A syn ND4 
C12705T syn ND5 
G12801A syn ND5 
C14766T l-T CYTB 
C14794T* syn CYTB 
- G14831A* A-T CYTB 
‘ C14915T* P-S CYTB 
A15266G syn CYTB 
A15244G l-V CYTB 
A15924G � MTTT 
C15978T* � MTATT 
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Table 6. (Continued) 
Case No Nucleotide position and Change Amino acid change Location 
T16136C : D-loop 
A16183C ~ D-loop 
T16189C � D-loop . 
A73G � D-loop 
T199C � D-loop 
316insC � D-loop 
A827G � RNRl 
A2706G ~ RNR2 
G4820A** ~ ND2 
G5237A* syn ND2 
G6023A syn COI 
T6216C* syn COI 
T6413C syn COI 
C7028T syn COI 
‘ A9272G syn C03 
C14766T T-I CYTB 
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Table 6. (Continued) 
Case No. Nucleotide position and Change Amino acid change Location 
Ti^ 71 del G* : D-loop 
A73G � D-loop 
A183G* � D-loop 
G263A � D-loop 
316 ins C ~ D-loop 
T16304C � D-loop 
A16309G � D-loop 
G16390A � D-loop 
T16519C � D-loop 
T1541C* � RNR2 
A2706G ~ RNR2 
A3744G * syn NDl 
‘ C3970T syn NDl 
A3769G* L-V NDl 
. G4769A syn ND2 
C4934T * syn ND2 
T6620C * syn COI 
C7028T syn COI 
A8452T** L-F ATP8 
G8860A . A-T ATP6 
C10736T* syn ND4L 
G11719A syn ND4 
T12714C* syn ND5 
‘ G13928C syn ND5 
‘ T 1 4 1 9 9 G P-T ND6 
C14766T T-I CYTB 
— G15Q43A syn CYTB 
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Table 6. (Continued) 
Case Nucleotide position and Change Amino acid change Location 
418 A73G : D-loop 
C150T � D-loop 
316insC ~ D-loop 
G499A � D-loop 
C16223T ~ D-loop 
C16257A ~ D-loop 
C16262T ~ D-loop 
C1749G* � RNR2 
A2706G ~ RNR2 
G4769A syn ND2 
G5231A syn ND2 
C7376T * syn COI 
C9500T* syn C03 
A12358A/G T-A ND5 
G12372T** syn ND5 
12455 insA frameshift ND5 
‘ C14766T T-I CYTB 
* stands for new mutations , ** for mutations that have been previously reported . "syn"= 
synchronous muta t ion ; "�”=muta t ion not found in protein-coding gene or indicates 
non-coding locus. Abbreviations used: D-Loop: Displacement Loop; RNR2: 16S rRNA; 
ATP8: ATP synthase 8; ATP6: ATP synthase 6; COS: Cytochrome c oxidase III; 
MTND4L: NADH dehydrogenase 4L; MTND4: NADH dehydrogenase 4; COI: 
Cytochrome c oxidase I; MTTD: tRNA Aspartic acid; COII: Cytochrome c oxidase II; 
NDl: NADH dehydrogenase 1; ND2: NADH dehydrogenase 2;ND5: NADH 
dehydrogenase 5; CYTB: Cytochrome b; MTTT: tRNA Threonine; MTATT: membrane 
attachment site. F: Phenylalanine T: Tyrosine D: Asparagine L: Leucine A: 
Alanine E: Glutamic acid Y Tyrosine C: Cysteine I : Isoleucine W: tryptophan 
M: Methionine H: Histidine R: Arginine V: Valine Q: Gin S: Serine 
N :Aspartic acid P: Proline K: Lysine G: Glycine 
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Table 7. Alteration patterns of mtDNA whole genome 
Functional Nucleotide Hep3B 109 111 115 418 Total Alteration Alteration 
location position alterations rate frequency 
(per l,000bp) 
D-loop 16024-576 14 7 5 9 7 42 100% T~5 
HVSl 16024- 10 3 0 2 3 18 80% 10.0 
16383 
HSV2 57-372 2 3 5 5 3 18 100% 11.4 
RNRl 648-1601 3 1 0 0 0 4 40% 1.5 
RNR2 1671-3229 5 2 1 2 2 12 100% 1.5 
NDl 3307-4262 3 0 4 3 0 10 60% 2.1 
ND2 4470-5511 0 2 3 2 2 9 80% 1.7 
CCI 5904-7445 11 4 1 2 1 19 100% 2.5 
MTTD 7518-7585 1 0 0 0 0 1 20% 2.9 
COII 7586-8269 3 0 0 0 0 3 20% 0.8 
ATP8 8366-8572 2 1 1 1 0 5 80% 4.8 
ATP6 8527-9207 2 0 1 1 0 4 60% 1.2 
ND3 10059-10404 2 0 0 1 0 3 490/0 1 2 
' C O S 9207-9990 0 0 0 0 1 1 20% 0.3 
ND4L 10470-10766 2 0 0 1 0 3 40% 2.0 
ND4 10760-12137 4 0 1 1 0 6 20% 0.3 
ND5 12337-14148 2 0 4 2 3 11 80% 1.2 
ND6 14149-14673 0 0 1 0 0 1 20% 0.4 
CYTB 14747-15887 6 1 5 2 1 15 100% 2.6 
MTTT 15888-15953 1 0 0 0 0 1 20% 3.0 
Ml ATT 15925-499 . 1 0 0 0 0 1 2 0 % 0.2 
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The number and frequency of alterations in the whole mt genome among individual 
functional regions were compared. Table 7 shows the distribution of the pattern of the 
alterations in the whole mitochondrial genome. The total number of base pairs divided 
the total number of alterations, and the alterations per 1,000 bases of each functional unit 
was obtained. In the D-loop region, a total of 42 alterations had been found, and all the 
five cases harbored D-loop alterations, the mutational rate was 100%. As far as 
mutational frequency is concerned, 7.5 alterations per 1,000 base pairs (bp) were found in 
D-loop while the alteration rate of coding region wasl .4 per 1,000 bp. Compared with the 
coding region as a whole, the alteration rate of D-loop was five times that of the coding 
region. The most frequent alterations occurred in the hypervariable segment 2 (HVS2), 
which was followed by the hypervariable segment 1 (HVSl), with a mutation rate of 80% 
and 100%, and a frequency of 11.4 per 1,000 base pairs and 10.0 per 1,000 base pairs, 
respectively. Therefore, the greatest frequency of mtDNA mutations was occurred in the 
—D-loop, especially in the region where HSV2 and HSVl is located. The hotspots in both 
the HVS2 and HVSl were further investigated，and remarkably, all the 5 whole genomes 
showed deletions or insertions in a mononucleotide repeat sequence 
(CCCC..CCCTCCCCCC) between nucleotides 303 and 316-318, which is inside the 
conserved sequence block II (CSBII) in the HVS2 (Figure 5). It could then be 
concluded that the hotspot iji the D-loop region, or the hottest spot in the whole mt 
genome, is located from nucleotides 303 to 318，which is known as the D310 region 
(Sanchez-Cespedes et al, 2001). This conclusion would be examined and confirmed in 
the subsequent experiment that focused on the D310 alterations in HCC with a bigger 
sample size. 
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Figure 5. The D310 region of D-loop (from Mambo et al, 2003) 
In the D-loop region, all mtDNA samples contained an A -4 G transition at nucleotide 
73 and C insertion or deletion between nucleotides 303 and 312. Four out of the five 
cases contained a G-4 A transition at nucleotide 263. But when I carefully search the 
database, the A transition at nucleotide 263 has been regarded to be normal, for an A 
in position 263 has been considered as a rare polymorphism in the Cambridge reference 
sequence. Thus, these 4 alterations were excluded. In the cell line Hep3B, the A G 
transition at nucleotide 73 was further analyzed. The result showed that it is a Chinese 
dominant polymorphism; this is consistent with my findings as all the HCC tissues were 
obtained from Hong Kong Chinese patients. 
In the mitochondrial-coding region, the region with the highest mutational frequency, 4.8 
per 1,000 base pairs, was found in ATP synthase 8 gene (ATPaseS). In addition, four out 
of the five cases were detected to be mutated, except the case No.418. There were five 
alterations found in these cases, including four A8452T mutations and one C8468T 
polymorphism. It suggested that the A8452T might be a common mutation in HCC. This 
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issue will be the focus of the section 3.3 for detection the mtDNA in the coding region. 
Other hotspots detected include the gene coding tRNA threonine (MTTT), tRNA aspartic 
acid gene (MTTD), gene coding cytochrome b subunit (CytB), COI gene and NDl gene, 
with the respective alteration frequency of 3.0，2.9, 2.6, 2.5, 2.1 alterations per 1,000 base 
pairs. Because ATP synthase consists of only 206 base pairs, and both MTTT and 
MTTD contain less than 100 base pair, the mutation frequency per 1,000 base pairs might 
not be a good criterion to detemine the true significance of their alterations. When the 
alteration rate of a specific gene/region was investigated, an alteration rate of 100% was 
found in 3 genes, RNR2, COI and CylB. The alteration rate of 80% was found in ND2, 
c o n , ATP8 and ND5 while that of other two genes (NDl and ATP6) was 60%. Besides, 
several common alterations in the coding region were found. An A750G in the RNRl and 
an A2706G in the RNR2 gene were detected in all 5 cases while a C14766T was found in 
4 out of 5 cases and a CI4766A mutation in the remaining 1 case. A C7028T 
polymorphism in the COI gene and an A8452T mutation in the ATP8 gene were found in 
3 out of the 5 cases. 
In fact, two new errors were recorded in the human mitochondrial Cambridge consensus 
sequence. The errors contain an A to G substitution al nucleotide 750 in the 12S rRNA 
gene and a single nucleotide deletion at nt 3107 in the 16S rRNA gene. Prezant et al 
(1994) concluded that is an A-->G np 2706 in the 16S rRNA gene is consensus change. 
Then none of these three alterations should be regarded as alterations from a strict 
perspective. Thus, neither of them should be taken into consideration in the research 
thereafter. Therefore, only three alterations were considered worthy of further reseach, 
i.e. C7028T, A8452T and C14766A. The C7028T was a polymorphism type in 
cytochrome c oxidase I gene and did not cause its amino acid change. In the 
mitochondrial DNA database (www.mitoinao.org). It was found that two types of 
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Chinese normal subjects harbored the same alteration of C7028T, so it might be 
predominant in the Chinese and was excluded for further analysis. The remaining two 
alterations should be meaningful because A8452T was a mutation in the ATP synthase 8， 
which caused a leucine to change to a phenylalanine al the amino acid position 29 of the 
ATPase 8. As for the C14766T, it was a rare polymorphism in the gene CytB that change 
a threonine to an isoleucine in the CytB, according to mitomap database. Hence, both 
alterations were concluded to be the major targets for the subsequent investigation in the 
coding region of the mtDNA genome. 
3.2 mtDNA D-loop mutation 
3.2.1 Screening of C-tract alteration in HCC and non-tumorous tissues by PCR 
Fragments Length Detection Assay (PFLDA) 
Using PCR fragment length detection assay, 12 out of 55 cases (22%) of the HCCs 
analyzed were found to have mobility shift between the non-tumorous and tumorous 
tissues (Figure 6). To confirm the results of length detection assay, those cases harboring 
somatic deletions/insertions were compared with one another for the sequence difference 
between the non-tumorous and tumorous D310 by direct sequencing (see results in Table 
11). 
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3.2.2 Identification of C-tract alterations by direct sequencing 
3.2.2.1 Identification of C-tract alterations in HCC and non-tumorous tissues by 
direct sequencing 
Twelve out of 55 cases (22%) of the HCCs analyzed harbored somatic 
deletions/insertions at this mono-cytosine repeals, and among them 92% (11/12) of the 
mutations were exclusively located in the C-tract region. In contrast to the published 
Cambridge Reference sequence, the 3'-C-repeat of the poly-cytidine microsatellite of all 
the studied samples contained six cytosines rather than five according to the database 
(hence CvTCe). Almost all mtDNA samples contained a C insertion between nucleotides 
311 and 312 except for 2 HCC tissues harboring a big deletion. According to Lohrer et al 
(2002), this discrepancy was due to a mistake in the Cambridge reference sequence, i.e., it 
should be Ce instead of C5. Most of them (9 out of 12) were 1 base pair deletion (4 cases) 
or insertion (5 cases). Two bp deletions were found in 1 case. Interestingly, additional 
mutations and deletions were found to accompany 2 cases: case 96 and case 397 (as 
shown in Figure 8). Case 96 showed a 10 bp big deletion: 5'-CCAAACCCCCCC-3' from 
site 300 to 309 (all" located in D310, including 7 bp cytocines), together with a C397G 
and a C343G. The case 397 with a 9 bp C-tract deletion (5'-CCCCCGCTT-3' from np 
311-319) showed an A300C mutation, but both the non-liimorous tissue and the tumor 
are highly heterogeneous at this point. And the big (>5bp) deletion was from base pair 
311-319, located in the D310, this included all 6 cytosines in the C-stretch from 311 to 
316 (Ce). This is the only mutation that was found at the C6 stretch with a big deletion 
and together with other comprehensive alterations. It seems that this €5 stretch is more 
stable than the C7 repeat of D310, and mutation occured m this region may result in big 
alterations, which requires further confirmation. One case without deletion/insertions 
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showed a 2 C to 2T (C303T, C304T) mutation within C-lracl and an A302T, as repeated 
by Manabu Nishikawa (2001). But it seemed to be a polymorphic site at the nucleotide 
489，7 out of 12 cases were a cytosine and 4 were thymine while Nashikawa's data 
showed that all were cytosine. Theses two alterations were still somatic mutations, 
because they were different between tumorous tissue and non-tumorous tissue. 
Interestingly in case 112, the base in the non-tumorous tissue was a T and that of the 
HCC tissue was a C. It was also intriguing that the level of heleroplasmy in those cases 
harboring bigger deletions (see case 397 and case 96 in Figure 7) was much higher than 
those with smaller alterations (case 387 and 39 in Figure 8). 
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Figure 6. PCR Fragment Length Detection Assay. 丁 strands for HCC tissue and N for 
paired non-tumorous tissue. PCR Fragments (106 bp) which contain the C-tract were 
analyzed on a denatured 6% PAGE, the shorter the sequence, the faster it moved. 
Instability at this C stretch gave rise to heteroplasmic sequences and resulted in band 
shifting or smearing in PCR products derived from tumour samples. Case 397 was found 
to have a big deletion while the other three had either insertion or deletion. After direct 
sequencing, it was confirmed that Case 397 harbored a 9 bp deletion, case 387 had a 1 C 
insertion; case 39 and case 72 each had a 1 C deletion. 
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387N,T(lbp inc.) ^ ^ ^ ^ ^ ^ ^ ^ 39N,T(ll»p del) _ _ _ _ _ _ 
A AG C G G 0 0 G G AG GOOO GOG ^ AG C 0 0 Q 0 0 0 AO G 0 0 G 0-0 9 0 T T T 
24 卩 250 240 250 
“h/wirtlWM 麵 ftiMrf 
AAOCGOGGOO AOO G 0 G 0 G G 0 T T TG AAOCOGGOOO AOOOGGGOOTTT 
240 250 240 250 
偏 I k m i k d m . 
Figure 7. Results of direct sequencing: T represents HCC tumor tissue, and N represents 
paired non-tumorous tissue. Case 387T had 9-cytosine in D310 while the non-tumorous 
tissue had just 8-C，i.e., a 1 bp insertion. And for the cases 39，harbored 1 bp deletion. All 
the samples were homoplasmic. 
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96N，T lObp del 9bp del 397N，T 
.AO X VI^ NO NN^ R, ^ . " 3GCC^GMGCGGGGGG/GGaGGGGGFIinGGN3GAAAmTrHa； 
:/!GAAGCGGGGGGA3GaGGaGGGTmffraNWATnTrri 210 220 230 240 25C 
) 240 250 260 271 
. 1 I 
- l i i i f r M i l i i i 
:/G A/GNGGGGGG ATGGGGG GMAITOT X3GCCN3G ASQGGGGGGNNIGGGGGNftANnTnNT 
‘ 240 250 230 240 250 26 
I Jill III, I 丨I Hm, r Iiil 
. . l E M i i _ _ _ 
Figure 8. Results of direct sequencing: T represents HCC tumor tissue, and N 
represents paired non-tumorous tissue. Case 97 T harbored a 10 bp deletion. 
(5，-AAACCCCCCC-3,).and case 397 had a 9 bp deletion (5’-CCCCCGCTT-3，). The 
non-tumorous and HCC tissues of these two cases exhibited strong heterogeneity in 
the mitochondrial ‘ DNA population. The multiple peaks shown on the sequencing 
graph suggest the presence of heteroplasmic alterations. However, the apparent 
heteroplasmic alteration may be attributable to the contamination of the surrounding 
non-neoplastic cells, because the DNA was not derived from a microdissected tumor. 
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3.2.3.2 Identification of C-tract alteration in PBMC of normal subjects by direct 
sequencing 
D310 C-tract region of 50 PBMCs from normal subjects were successfully sequenced. 
One case (2%) was found to have 6 bp cytosine in the D310 C-tract, 22 (44%) cases had 
7 bp, 20 cases (40%) had 8bp and 6 (12%) had 9bp. One case that harbored mutations in 
this D310 region was rendered difficult to identify the exact cytosine number of its 
C-tract. The D310 region of Case No.29 had mutated to Cn instead of CeTC?, and the 
definite mutation that could be decided as a T302C. 
3.2.3.3 Identification of C-tract alteration in PBMC of HCC patients by direct 
sequencing 
„ To differentiate between other somatic cells and the hepatocyte, D310 C-liact region of 
17 PBMCs from HCC patients were also sequenced. It was found that 1 case (5.9%) had 
6 bp, 6 cases (35.3%) had 7 bp, 4 cases (23.5%) had 8 bp and 6 cases (35.3%) had 9 bp in 
this C-tract. 
3.2.4 Statistics of the analysis of C-tract alterations 
The relationship among C-tract polymorphism, the c-tract mutation frequency and their 
correlation with HCC were further investigated. The polymorphism pattern of the 
resected HCC samples were compared with that of their paired non-tumorous tissue. As 
shown in Table 8, the occurrence of C-tract type of 6 bp, 7 bp, 8 bp, 9 bp cytosine were 0 
(0%)，30 (54.5%), 21 (38.1%) and 4 (7.3%) in the adjacent non-lumorous tissue of the 55 
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cases, while that in the HCC tissue were 1 (1.8%), 30 (54.5%), 18 (32.7%), and 3 (5.5%), 
respectively. The constitution of the polymorphic pattern was of no difference (Table 8). 
Also，the percentage of 7bp type of D310 in tumor tissue was the same as that of adjacent 
non-tumorous tissue; this indicates that despite many HCC tissues having undergone 
D310 mutation, the pattern of polymorphism remains unchanged. D310 polymorphism 
type seems to have no implication on the susceptibility towards HCC. The polymorphism 
types of C-tract, especially the D310, from the PBMCs of 50 normal subjects and 17 
HCC patients showed no significant difference between the 7 bp type and non-7 bp type 
(Table 11). 
Subsequently, the polymorphism types among the resected samples were compared. The 
results showed that in the paired non-tumorous tissue (Table 9), the D310 without 
alterations were more likely to be 7-cytosine type than those with alterations (63.4% vs 
• 21.4 %, P<0.01). In the HCC tissue samples, similar results could be observed. HCC 
samples with no alterations in D310 were more likely to be 7 bp cytosine type than those 
with alterations (63.4% vs 28.6%, P < 0.05) (Table 10). It can be concluded that the 7 bp 
cytosine type of C-tract is less susceptible to C-tract alteration in the HCC liver tissues 
(both tumorous and non-tumorous tissues). 
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Table 8.C-tract polymorphism pattern in resected liver tissues 
C-tract polymorphism type 
Liver tissues 6bp 9bp 
Non-tumor (n=55) 0(0%) 30(54.5%) 21(38.1%) 4(7.3%) 
Tumor (n=55) 1(1.8%) 30(54.5%) 18(32.7%) 3(5.5%) 
X2 = 0.00, P> 0.05 
Table 9.C-tract polymorphism pattern in non-tumorous tissues 
C-tract polymorphism type 
•Non-tumor (n=55) 6bp 7bp 8bp 9bp others 
•Non-alteration (n=41) 0 ( 0 % ) 2 6 ( 6 3 . 4 % ) 14(34 .2%) 1(2 .4%) 0 ( 0 % ) 
- DAlteration (n=14) 0( 0%) 3 ( 2 1 . 4 % ) 7 ( 5 0 % ) 3 ( 2 1 . 4 % ) 1(7.2%) 
Non-tumorous 7bp Non-7 
No alteration 26 15 
Alteration 3 11 
X2 =7.38, PO.Ol 
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Table 10. C-tract polymorphism pattern distribution in HCC tissues 
C-tract polymorphism type 
•HCC (n=55) 6 bp 7 bp 8 bp 9 bp others 
oNon-alteration(n=41) 0(0%) 26(63.4) 14(34.2%) 1(2.4%) 0(0%) 
•Alteration (n= 14) 1(7.1%) 4(28.6%) 4(28.6%) 2(14.3%) 3(21.4%) 
HCC 7bp Non-7 
No alteration 26 15 
Alteration 4 10 
X2 =5.11,P<0.05 
m 
Table 11. Distribution of C-tract polymorphism pattern in PBMCs of normal subjects and 
HCC patients 
C-tract polymorphism type 
PBMC 6 bp S ^ 9 bp 
Normal (n=50) 1(20.0%) 22(44.0%) 20(40.0%) 6 (12%) 
HCC (n=17) 1(5.9%) 6(35.3%) 4(23.5%) 6(35.3%) 
PBMC 7 bp non-7 bp 
Normal ‘ 22 28 
HCC 6 11 
X2 =0.395, P> 0.05 
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Table 12.Results of D-loop Alteration 
Case No. Nucleotide Change Change type 
39 C9TC6-C8TC6 IC deletion 
45 C8TC6-C9TC6 IC insertion 
A297C* transversion 
T489C transition 
72 C8TC6-C7TC6 IC deletion 
T489C transition 
86 C8TC6-C7TC6 IC deletion 
T489C transition 
94 C8TC6-C7TC6 IC deletion 
C397G transversion 
T489C transition 
96 295:304 deletion including lObp deletion 
C9TC6-C5TC6 
111 C7TC6-C8TC6 1C insertion 
T489C transition 
‘ C271T transition 
112 C297A* transversion 
C8TC6-C7TC6 IC deletion 
T489C* transition 
117 C7TC6-C8TC6 1C insertion 
T4..89C transition 
360 C343G* transversion 
A475G . transition 
387 C7TC6-C8TC6 IC insertion 
397 A297C* transversion 
A300C* transversion 
311:319 deletion 9bp deletion 





Note: * is anew mutation not previously reported . Abbreviations as shown in Table 6. 
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3.3 Results of coding region mutation 
First, PGR were used to amplify the five genes encoding the respiratory chain subunits, 
CytB, Coll, NDl, ND4, and ND5 of mtDNA in 55 HCC tissue samples, and then SSCP 
were performed for these 5 respiratory subunit genes to screen for the mutations (see 
Figure 9 and Figure 10). Results showed that 47.3% of CytB (26 out of 55 cases), 34.5% 
of ND4 (19 out of 55), 29.1% of ND5 (16 out of 55), 21.8% of NDl (12 of 55) and 
16.4% of Coll (9 of 55) harbored mutations (As shown in Table 13). 
In addition, the mutation pattern of both the D310 region and the five respairatory subunit 
genes were compared (results shown in Table 14, 15). Finally, to confirm the mutations 
detected by SSCP, five cases of each gene were randomly selected to undergone direct 
sequencing. Findings were summarized in Table 16. 
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Figure 9. Example of SSCP results of CytB. T strands for HCC tissue and N for paired 
non-tumorous tissue. All samples are paired. DNA Fragments were analyzed on 6% PAGE, 
a mutation was considered if there were any mobility shifts in bands between tumorous 
tissue (T) and paired non-tumorous tissue (N) of one of the fragments. Those have the 
same bands shift in both the paired tissues (N and T) compared with others were regarded 
as harboring polymorphism. The white triangle indicates a polymorphism, and the two 
black arrows represent two mutations in case 426 and case 427. The control was not 
denatured and fragments of it are all double strands. So the bands of double strand (white 
arrows) can be distinguished from those of single strand. 
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Figure 10. Example of SSCP results of Coll. T stands for HCC tissue and N for paired 
non-tumorous tissue. A mutation is shown in case 112, and a polymorphism in case 115. 
Black arrow: mutation; white triangle: polymorphism; white arrow: double strand 
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Table 13. SSCP results of 5 genes coding the respiratoiy siibuiiits. 
Case No. CYT-B COII ND-1 ND-4 ND-5 
26 M - M P M3 
38 - M P 
39 M P P p 
43 M M P 
45 M M, P - - p 
46 M M p 
65 - M M, P P 
72 P - M M P 
86 P M - M，P P 
88 M, P M - M -
89 M, P - - M p 
91 P P p 
94 - M M M 
95 - - - - _ 
96 - P - - . 
98 P M - . 
, 99 - - - - . 
103 - p 
106 - M M -
109 M M M M M 
104 M - . 
111 M M M M 
112 M M M -
113 M P M p 
114 M ' M M -
115 M M P M M 
117 M - - M 
360 M 
368 - M, P - _ 
370 M P P . 
372 M P P M -
376 P P - . 
381 - - M M 
382 P p 
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Table 13. (Continued) 
Case No. CYT-B COII ND-1 ND-4 ND-5 
383 M, P M - -
384 - P P 
385 M - M -
387 P P 
389 - P M 
395 M - - P -
396 - M - P 
397 - -
406 P -
408 M P P - M 
411 P - M 
412 M - -
420 P M M 
413 - -
414 M - P M 
418 M - M M 
419 M - - M 
‘ 422 P - - - M,P 
425 P - - M -
426 M M P 
42 7 M - - - p 
P represents polymorphism;.M represents mutation and indicates no alteration were 
found. To clarify the relationship between D-loop and the coding mutation, 2 types of 
statistical tests for related samples were performed based on data represented in this Table 
and the data of D310 mutation status. When presence of mutation (M) =1 and those 
without mutation = 2, the data were transferee! to categorical data to facilitate 
nonparametric test. 
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To investigate the relationship between the mutation pattern of D310 and the five genes in 
the coding region, and to find any association between them, SPSS was used. 
First, Friedman Test was used to compare the distribution of the mutations (mutation 
pattern) among all the 6 regions (D310 and 5 coding genes). Tests for several related 
samples (NPar Tests) of non-parametric test were performed. Results were shown in 
Table 14. All tests showed that the distribution of the 6 regions was significantly different 
(P=0.028<0.005), which meant that there are differences among the mutation pattern of 
these six regions. To find out the specific difference, Wilcoxon Signed Ranks Test (Tests 
for two related samples) of non-parametric test was utilized to address the difference 
between each one another (as shown in Table 15). The test revealed that the mutation 
pattern of CytB was significantly different from those of Coll (P=0.003), NDl (P=0.06), 
D310 (P=0.()34), and ND5 (P=0.041). For the relationship between CytB and NDl，the P 
, value was marginal (p二0.06)，so their mutation pattern is similar while others were 
significantly different from each other. Which might indicate thai both NDl and CytB 
were more frequently mutated than other coding genes. 
Subsequently, five cases of each of these five genes were randomly selected and direct 
sequencing was performed to confirm and identify the results of the SSCP screening. In 
addition, two other "hotspot" candidates, A8452T in ATP8 gene and C14766T in the 
CytB gene, were recruited (as in the former part). 
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Table 14. Friedman test for relationship between D-loop mutation and coding region 
(Test for Several Related Samples) 
Ranks (n=55) Mean Rank 
D310M 3.59 
CYTB 2.99 




X2= 12.515, df = 5, P= 0.028 (Asym. Sig.) 
Table 15. Wilcoxon signed ranks test for relationship between D-loop mutation and 
coding region (Test for 2 related samples) 
‘ CYTB - c o i l - N D l -ND4 -ND5 -COII - N D l -ND4 -ND,^ - N D l -ND4 - ND5 ND4 -ND5 ND5 
D 3 1 0 M D 3 1 0 M D310M D 3 1 0 M D 3 1 0 M CYTB CYTB CYTB CYTB COII COII -COII N D l - N D l ND4 
Sign -2.117 -.728 -.688 -.784 -.209 -2.985 -2.746 -1.400 -2.041 .000 -1.606 -.816 -1.460 .943 -.600 
Asymp. .034 .467 .491 .433 .835 .003 .006 .162 .041 1.000 .108 .414 .144 .346 .549 
Sig. 
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Table 16. Sequencing result of mtDNA coding region alterations 
Gene Case Nucleotide position and Previous report Amino acid 
No. Change change 
CYTB 39 C14766T (rare p o l y m o r p h i s m ) � T-I 
A15326G ~ T-A 
43 T14783C Breast Cancer syn 
G15043A ~ syn 
A15218G ~ T-A 
G15301A � syn 
A15326G ~ T-A 
45 C14766T (rare p o l y m o r p h i s m ) � T-I 
C15043A � syn 
T15255G/T* � V-G 
T15262T/G* � S-Ter 
A15326G � T-A 
46 C14766T (rare polymorphism) ~ T-I 
A15326G � T-A 
88 C14766T (rare polymorphism) ~ T-I 
A15326G � T-A 
C15658T* � syn 
c o i l 45 T7684C � syn 
G7853A � V-I 
86 T7684C ~ syn 
G7853A � V-I 
88 A8149G* ~ syn 
98 A7828G � syn 
G7912A. � syn 
109 8281:8289 9 bp deletion* 8271-8281 9bp del �(Non-coding) 
NDl 65 G3316A** NIDDM; LHON; A-T 
PEO 
- 3707 insG* � RAVOQ-RSSPK 
3717 del C* � #134-138/319 
94 3707 insG* � RAVOQ-RSSPK 
3717 del C* ~ #134-138/319 
109 3717 del C* � iYameshift 
112 3707 msG* � RAVOQ-RSSPK 
3717 del C* ~ #134-138/319 
418 G3255C/G* � � ( t R N A for 
94 . 
leucine) 
Table 16 (Continued) 
Gene Case No. Nucleotide position and Previous report Amino acid 
Change change 
ND4 360 T10535C* - syn 
372 10483delA* � #5/99 
420 10483delA* � #5/99 
425 T11233C* � syn 
426 T10535C* � syn 
A11267G/A* � T-A 
T11490G* � M-Ter #244/460 
ND5 109 T12611V* - V_E 
C12705T - syn 
115 T12714C* � syn 
419 C12705T � syn 
420 A12849G* � syn 
422 C12705T � syn 
C13371C/G* � syn 
A13372A/T* � 1-F 
Note :** represents mutations represents new mutation the others were 
polymorphism. means not previously reported. 
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Because sequencing is an expensive and time-consuming technique, 5 cases from each of 
the 5 respiratory chain subunit genes that had been screened to be mutated in SSCP were 
randomly selected and then sequenced to confirm the results of it. Each of these cases 
was proven to harbor mutation(s), or at least alterations. Since the paired non-tumorous 
tissue were not sequenced, the alterations were compared with the Cambridge reference 
sequence, so an alteration can not be definitely distinguished as a mutation or just 
polymorphism. However, all the selected cases showed alterations in SSCP were proven 
to harbor alterations by direct sequencing. 
In the 25 cases selected to be sequenced, a total of 50 alterations were identified. There 
included 24 mutations and 26 polymorphisms. Forty out of 50 alterations were base 
substitutions and the other 10 were deletions/insertions. Eighty percent (32 from 40) of 
the substitutions were A-G or C-T transitions, including 10 of the 14 mutations and 22 of 
the 26 polymorphisms. While 83.3% (20/24) of the mutations and 92.3% (24/26) of the 
‘ polymorphisms were homoplasmic. These findings were concurred with earlier studies 
on the whole mt genome. Eight transversions were found in all the 50 alterations, 4 of 
them were mutations and the remaining 4 were polymorphisms. 
For the gene CytB, an A15326G was found in all the 5 cases, which resulted in an amino 
acid alteration from threonine to alanine in position 194 in the cytochrome B subunit. In 
addition，eight out of 10 CytB genes were detected to have a C14766T alteration. These 
10 CytB genes included four cases from the five CytB genes in SSCP group, together 
with the four CytB genes from five whole genome sequences. Besides, the whole genome 
in case 111 had a C14766A mutation. And for the remaining 1 case, case 43，the 
nucleotide in position 14766 in the CytB gene could not be determined upon sequencing. 
On the whole, there were 9 alterations (90%) in nucleotide 14766 of 10 CytB genes; this 
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site can be undoubtedly considered as another hotspot il�ihe paired non-tumorous ones 
are all Cs. 
A 9bp deletion at np 8281-8289 in MTNC7 were also be found, which is located in np 
8270-8294, a non-coding region between MTC02 and MTTK. ll is in the vicinity of a 
10 bp deletion at np 8271-8281,which was documented that the frequently deleted in 
more than 700 subjects (hltp:"�vww’mUomap’org/cgi-bin/mitomap/tbll()gen.pn. But it is 






4.1 The whole genome mutation 
This study showed there were frequent mutations located in the mtDNA in the 5 cases. A 
total of 150 alterations had been found in these 5 mt genomes, and that is in concordance 
with others in that nearly two-thirds of the tumors showed mtDNA abnormalities (Polyak 
et al, 1998; Fliss et al, 2000; Habano et al, 2000). The mutational rate of mtDNA is at 
least 10 times higher than nuclear DNA (Wallace, 1994), although the alterations of 
mtDNA in tumors have received much less attention (Green and Reed 1998). There are 
three reasons for the high mutation rate of mtDNA: (1) it lacks protective histone in its 
molecule, which makes mtDNA naked and susceptible to mutations. (2) The mtDNA is 
continuously exposed to reactive oxygen species (ROS) generated during oxidative 
phosphorylation (Richter et al, 1995). (3) There is a less efficient DNA repair system for 
mtDNA when compared with nuclear DNA (Croteau et al, 1997). Besides, mtDNA 
molecules have multiple copies per cell (10-1,000 per cell), and yield a massive effect 
over nDNA. All these gives raise to mt genome mutations a rate of 10- to 100-fold higher 
than the nDNA mutation rate (Brown et al, 1979). The mtDNA is thus an ideal target for 
seeking mutational hotspots. 
One hundred and twenty-nine of the 150 alterations (86%) detected in this study were 
polymorphisms of G- to- C or T-to-A transitions. There were nearly equal chances for 
both C-to-T or T-to-C and A-to-G or G-to-A transitions. For the alterations of oxidative 
damage were generally transitions affecting G residues, which are the preferred targets 
for oxidative damage to DNA in general and in particular, mtDNA. The data also imply 
ROS involved in mtDNA mutation. This is also agreed with the known mutagenic spectra 
of oxidative damage (Beckman et al, 1997; Polyak et al, 1998; Gentil et al, 2000). This 
study support the suggestion that mtDNA alterations or mutations resulted from the 
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reactive oxygen species (ROS) continually generated in the mitochondrial, especially 
during OXPHOS. On this basis, the mutation on the mtDNA genes encoding respiratory 
subunits would also become a focus of interest, because any alterations on the genes may 
cause protein impairment of the respiratory chain subunits. and Ihus damage the electron 
transportation on the chain. As a result, ATP synthesis is reduced, defective of oxidation/ 
phosphorylation coupling would produce abnormally elevated dose of ROS. According to 
Goldman (1996), an agent may have beneficial effect at a low level exposure but may be 
harmful at high-level exposure; this notion may be relevant for some oxidative stresses. It 
has been suggested that exposure to slightly elevated level ROS can be mutagenic and 
induces mitosis while that of high-level ROS can cause apoptosis (Wallace DC, 2001). 
Most of the endogenous toxic reactive oxygen species (ROS) are generated as 
by-products during the process of oxidative phosphorylation (OXPHOS) in mitochondria 
(Raha and Robinson, 2001). The mitochondria oxidize h\drogen to generate water and 
ATP (Figure 11). Reducing equivalents in the form o�hydrogen are recovered from 
carbohydrates by the tricarboxylic acid (TCA) cycle The resulting electrons are 
transferred to NAD+, to give NADH + H+，or to flavins located in an iron-sulfur (Fe-S) 
center containing “enzymes that interface with the electron transport chain (ETC). 
Electrons donated from NADH + H+ to complex I (NADH dehydrogenase) or from 
succinate to complex II (succinate dehydrogenase (SDH)) are passed sequentially to 
ubiquinone (coenzyme Q (CoQ)) to give ubisemiquinone (CoQH ) and then ubiquinol 
( C 0 Q H 2 ) . Ubiquinol transfers its electrons to complex HI (ubiqumol:cytochrome c 
oxidoreductase), which transfers the electrons to cytochrome c. From c>lochrome c the 
electrons move to complex IV (cytochrome c oxidase (COX)) and finally to Vi O2 to give 
H2O. The energy released by this ETC is used to pump protons out of the mitochondrial 
inner membrane, creating the transmembrane electrochemical gradient ( A T ) . The 
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potential energy stored in A平is used to condense ADP and Pi to make ATP via complex 
V (ATP synthase), which is driven by the movement of protons back through a complex 
V proton channel. 
A superoxide anion (O2') is generated from OXPHOS by ihe transfer of one electron 
from the ETC to O2 (Figure 11). The O2" is convened to H2O2 by Mn superoxide 
dismutase (MnSOD) or cytosolic Cu/ZnSOD, and the resulting H2O2 is reduced to water 
by glutathione peroxidase (GPxl) or catalase. In the presence of reduced transition metals, 
H2O2 can be converted to the highly reactive hydroxy 1 radical (OH). Major targets of 
ROS reactivity are the Fe-S centers of the TCA cycle and ihe ETC. Hence, mitochondria 
are particularly sensitive to oxidative stress (Wallace, 1999). 
Cancer cells exhibit an active OXPHOS pathway producing a marked increase of ROS 
(Bianchi et al, 2001). The DNA breakdown products by free radicals (lipid peroxides, 
, alkoxyl radicals, peroxyl radicals, and aldehydes) mainly occur at the mt membrane level 
and free radicals preferentially damage the single chain of the tnpie-stranded DNA 
structure of the D loop (Hruszkewycz et al, 1988). 
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Figure 11. Diagram showing the relationships of mitochondrial OXPHOS to: (1) energy 
(ATP) production, (2) ROS production, and (3) initiation of apoptosis through the mtPTP. 
• The OXPHOS complexes, designated I to V，are as follows: complex I (NADH: 
ubiquinone oxidoreductase), encompassing a FMN and six Fe-S centers (designated with 
a cube); complex II (succinate: ubiquinone oxidoreductase), involving a FAD, three Fe-S 
centers, and a cytochrome b; complex III (ubiquinol: cytochrome c oxidoreductase), 
encompassing cytochromes b, c l , and the Rieske Fe-S center; complex IV (cytochrome c 
oxidase), encompassing cytochromes a+as, CuA, and CuB; and complex V 
(H+-translocating ATP synthase). Pyruvate from glucose enters the mitochondria via 
pyruvate d ehydrogenase (PDH), generating a cetyCoA, w hich e nters t he T CA c ycle b y 
combining with oxaloacetate (OAA). Cis-aconitase converts citrate to isocitrate and 
contains a 4Fe-4S center. Lactate dehydrogenase (LDH) converts excess pyruvate plus 
NADH to lactate. Small molecules defuse through the outer membrane via the VDAC or 
porin. The' VDAC, together with ANT, Bax, and the cyclophilin D (CD) protein, are 
thought to come together at the mitochondrial inner- and outer-membrane contact points 
to create the mtPTP. The pro-apoptotic Bax of the mtPTP is thought to interact with the 
anti-apoptotic Bcl2 and the benzodiazepine receptor (BD). The opening of the mtPTP is 
associated with the release of CytC, which activates Apaf-1, which then binds to and 
activates pro-caspase-9. The activated caspase-9 then initiates the proteloytic degradation 
of cellular proteins (adapted from http://www.mitomap.org/mitomap/mito_apop.pdf). 
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Experimental and epidemiological evidences suggest that DNA oxidation is mutagenic 
and is a major contributor to human cancer through three major sources: smoking, 
chronic inflammation, and endogenous oxidants such as leakage from mitochondria 
(Ames et al, 1995; Jocab et al, 1996; Hagen et al, 1997). There are more and more 
evidences of oxidative damage during carcinogenesis. 
Cigarette smoking has long been identified as the major risk factor for cancer. Cigarette 
smoke contains high levels of NOx and depletes the body's antioxidants, and phagocytic 
cells recruited to sites of chronic infection generate abundant reactive oxidants such as 
NOx and HOCl. Oxidative stresses caused by these oxidants may contribute to as much 
as half of all human cancers. Most recently, it has been shown that elevated DNA 
oxidation has been measured during early Helicobacter pylori infection in the proceeding 
of stomach cancer, ferric nitrilotriacetate administration in experimental rodent renal 
. cancer, smoking in lung cancer, and exposure to diesel exhaust particles in lung cancer, 
asbestos in lung cancer, benzene in leukemia (Liu et al, 1996; Hiraku et al, 1996), and 
aflatoxin in liver cancer (Shen et al, 1995). Many studies have provided more than a 
simple association between carcinogenic agents and oxidative DNA damage by 
measuring the specific induction of repair enzymes by oxidative carcinogens (Janssen et 
al, 1993) and by demonstrating the suppression of carcinogenesis by administration of 
antioxidants (Wargovich, 1997). The latter results are consistent with the strong 
correlation between a high intake of fruits and vegetables, which are the major source of 
dietary antioxidants, and reduction in cancer risk by half (Ames et al, 1995). Fraga et al 
(1996) have reported elevated oxidative damage to sperm DNA in smokers and in men on 
low serum antioxidants (vitamin C) and thus hypothesized that it causes cancer and birth 
defects in the children of male smokers. This was confirmed by many studies (Sharara et 
al, 1998). Besides, new epidemiological evidence indicates that all types of childhood 
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cancer studied are increased in offspring of male smokers. For example, the risks of acute 
lymphoblastic leukemia, lymphoma, and brain tumors are increased three to four times (Ji 
BT et a., 1997). The data of this research indicates that oxidative damage causes most of 
the mtDNA mutations in HCC, and may play an important role in hepatocarcinogenesis. 
Although the ROS oxidative damaging induces mutation, human body has its 
mechanisms to correct it, one of which is base excision pathway. Base excision repair 
(BER) is likely to be the main mechanism involved in the enzymatic restoration of 
oxidative base lesions within the DNA (See details in the sectionl.2.3). Enzymes such 
as Escherichia coli endonuclease 111 (endo III) and formamidopyrimidine DNA 
N-glycosylase (Fpg), recognize and excise several oxidized pyrimidine and purine bases, 
respectively, and possess associated lyase activities that result in strand cleavage. The 
latter enzyme is one of three gene products in the coordinated "GO system" (mutM, mutT, 
, mulY), a set of three repair enzymes that suppress mutagenesis by Guanine Oxidation, by 
removing 8-oxo-guanine (0x08Gua) paired with cytosine (mutM), adenine paired with 
oxoSGua (mutY), and by hydrolyzmg the oxidized nucleotide oxoSdGTP to the 
nucleoside monophosphate (mutT), thereby preventing its incorporation into DNA 
(Demple and Harrison, 1994; see also section 1.2.3), Therefore, there must be both the 
oxidative damage and insufficient repair, which leads to mtDNA mutation in HCC. 
Among these variants, 31 alterations were predicted to alter the amino acid sequence of 
the encoded protein, 55 variants in the protein coding regions were silent, 16 variants 
were predicted to affect rRNA (15 variants) or tRNA genes (1 variant), and 8 were 
predicted to affect ATP synthase (4 for ATPaseS, and 4 for ATPase6) as well as 2 
frameshifts being predicted to affect CytB and ND5 genes. In addition, only one mutation, 
a C15978T was identified to influence the mitochondrial membrane attachment site 
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(MTATT) in the cell line Hep3B (Table 6). 
From Table 7，the distribution on the mtDNA genome of somatic mtDNA variants found 
in this study could be summarized. Obviously, the highest alteration took place in the 
D-loop region, in particular, the D310. It is of interest that mutations were detected only 
in the D310 repeal but not in other mitochondrial microsatellites sites such as a (CA)n in 
the np 514. This issue will be further addressed in the D310 mutation section. While in 
the coding region, the high frequency variants were located in the COI, RNR2, CytB, 
ND5 and NDl. A2706G is considered as a polymorphyism in the Cambridge reference 
sequence, but all the nucleotide changes al 2706 in 5 cases were found to be guanine. 
A27()6G causes no amino-acid change and in fact should be regarded as the consensus 
type. The number of actual variants of all the 5 whole mt genome in RNR2 fell to 7 in 
total. As a result, the regions of frequent alteration were the other 4 genes in respiratory 
.. chain, namely, COI, CytB, ND5 and NDl. The regions which have low frequency of 
variation included COII, COS, and ND6，with a total variation of 1，1 and 1 respectively. 
As the sample size (n=5) was too small, the variant patterns of mtDNA mutation needs to 
be investigated in a larger scale. 
It is intriguing that an A8452T located in the ATPase 8 was a consistent mutation in 80% 
(4 out of 5) of the cases in both HCC tissues and cell line. This mutation caused a leucine 
change to a phenylalanine in the 29山 amino acid of ATPaseS. In addition, a cytosine in 
the nucleotide 14766 in the CytB gene was 100% changed when compared with the 
Cambridge reference sequence. Four of the five cases harbored C14766T variation and 
one had a CI 4766A mutation. C14766T caused the 7th amino acid of the cytochrome b 
to change from isoleucine to theronine which is considered as a polymorphism, while the 
mutation CI4766A caused isoleucine to asparagines. These two sites were anticipated to 
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be the mutation/alteration hotspots of HCC. This notion would be examined in the 
following section. 
In this section, it can be concluded that the C-tract of D310 region is a possible hotspot, 
and an A8452T as well as CI 4766A might be hotspots. The D-loop region of mtDNA is 
important in the replication process of mitochondria DNA (Clayton, 1982), in this regard, 
it is interesting to find a high frequency of mutations and deletions in D310 in mtDNA of 
tumor ceils. Further investigation about D310 C-tract mutation as well as the rate of 
mutations in other mitochondrial regions in larger-scale would be performed in the 
following study. 
It is also worth considering that alterations of Hep3B (67 vs 17,17,27,27, respectively) 
were much higher than those of other 4 HCC tissues. To confirm whether these variants 
.. were specific of cancer cells or merely the result of in vitro conditioning, Polyak et al 
(1998) tested the primary cancer cells from which the cell lines were derived and also the 
normal colon tissue counterparts. They found that 12 of the 88 mutations were specific 
for tumor cells. Polyak et al. thus concluded that the difference between the cell line and 
HCC tissues were due to their own pathological and clinical features, and not caused by 
the difference between cell line and tissue. Thus, the difference between the cell line 
Hep3B and 4 HCC tissues in this study are acceptable and the results of both HCC cell 
line and tissues were comparable. 
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4.2 mtDNA D-loop mutation 
The existence of D310 changes in 55 primary HCCs was determined. Twenty-two 
percent of the HCCs analyzed harbored somatic deletions/insertions at this 
inono-cytosine repeats, and among them 92% (11/12) of the mutations were exclusively 
found in this C-tract region. Therefore, Ihe D310 mononucleotide repeats in mtDNA. in 
particular the C-tract, is a hot spot for somatic deletions/insertions in Chinese HCC. 
It IS important to know the biological significance of the C-tract mutation after it has been 
identified as a mutation hotspot. Since the C-tract is a mono-cytosine repeat, it is 
reasonable to consider it as a microsatellile (MS) repeat and mutation in this region as 
microsatellite instability (MSI). There are a variety of tumors exhibiting an abnormally 
high rate of spontaneous mutations which result from malfunction of DNA mismatch 
repair (MMR) genes; these are identified as nuclear genome instability (nGI). The most 
‘ common form of nuclear genome instability is the appearance of novel, noninherited 
microsatellile alleles in tumor cells. MSI can be identified by change in length produced 
by the insertion or deletion of one or more repeat units in tumor tissues as compared with 
MS alleles in n.on-lumorous counterpart tissues. Such sites are frequently found in 
mtDNA, for example, the D310 region. To investigate the mtDNA microsatellite 
instability, the markers for mitochondrial genome instability (mtGI) used should be point 
mutations, length-tract instability of mono- or dmucleotide repeats, mono- or dinucleotide 
insertions or deletions, and long deletions. Comparison of non-tumorous and tumorous 
tissues from the same individual reveals that mt-mutations may show as homoplasmic 
. Call tumor cells have the same variant haplolype) or as heteroplasmic (tumor cells are 
a mosaic of inherited and acquired variant haplotypes). Since D310 contains 
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mononucleotide repeats and its variations are cytosine deletions/insertions, this alteration 
in C-tract was also defined as mlMSI. 
So far, many investigations have been performed to address the mtMSI and many mtMSI 
sites have been found. Szibor et al (1997) found that in normal individuals, starting at 
514 bp of the mtDNA control region, there is a (CA)n microsatellite showing 5 haploid 
alleles differing in size by the number of dinucleotide repeat. Heerdt et al (1994) tested 
24 pairs of normaJ/colorectal cancer tissues and found no allelic change in the mtMS. 
Extending from 16,184 bp to 16,193 bp of the mtDNA control region, there is a poly(C) 
tract interrupted by a T at the 16, 189 bp position (Anderson et al, 1981). Bendall et al 
(1995) observed that one of the mt variants that usually occur in normal individuals is the 
appearance of an uninterrupted poly(C) tract due to aT-^C transition at 16,189 bp; these 
cases also showed length heteroplasmies of the poly(C) tract. 
However, like Heerdt etal (1994), I did not found (CA)n microsatellite and poly(C) tract 
alterations in other regions other than the D310 region in the mtDNA. Heerdt et al 
‘ sequenced a fragment of the ml-D loop (371-570 bp) and analyzed the appearance of 
allele changes in the (CA) n mtMS in 24 pairs of normal/tumor tissues of colorectal 
cancers, and found no tumor mutations. Also, Habano et al (1998) analyzed the (CA)n 
mtMS and the D loop poly(C) tract in 45 pairs of normal/tumor tissues from sporadic 
colorectal cancers. No (CA)n mtMSI was detected m the tumor tissues. Observations of 
mtMSI in various cancers have been conflicting. Tan et al (2002) investigated the 
mtDNA MSI by both TTGE and by sequencing methods. He found that insertion and 
deletion were delected only in the D-loop region of np 303-309 where the stretch of 7 Cs 
was located. Similar to my data, MSI was not detected in any of the other 10 short tandem 
repeat (STR) regions. Besides, three specimen pairs had T16189C substitution that 
resulted in a stretch of 10-13 Cs in the region. None of them showed obvious insertion or 
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deletion of Cs. From these observations, they proposed that the np 303-309 is probably a 
mutation hot spot rather than the reflection of a true MSI. 
Some studies analyzed both the nuclear microsatallite instability (nMSI) and the mtMSI. 
Richard et al (2000) analyzed 40 pairs of normal/cancer breast tissues for the presence of 
mitochondrial (mt) genome instability and nuclear MSI in tumor cells. For mt, markers 
used included a (CA)n mt microsatellite (MS) starting at the 514-bp position of the D-
loop region and 4 informative Mnl\ sites located between the 16,108- and 16,420-bp 
positions of the D loop region. Nuclear microsatallite instability (MSI) was tested with 8 
(CA)n MS. Moreover, they tested the spontaneous frequency of mtMSI and mt-Mw/I 
mutations. A 216-fold increase of mutation rate over the spontaneous rate in the female 
germline was found in m{-Mnl\ sites. Instability of the mtMS occurred with a 16-fold 
increase over the rate of spontaneous mutations. Nuclear MSI was found in 20 of 40 (50%) 
cases. Analysis of the correlation between mt and nuclear mutations showed no 
" significant associations, suggesting thai different systems are responsible for mt and 
nuclear genome instability in tumor cells. They proposed that the two main mechanisms 
producing mtRFLP and mtMSI are (1) damage induced by free radicals and (2) error 
repair by the polymerase y, an enzyme with decreased proof reading efficiency (Kunkel 
et al, 1985; Pinz et al, 1995). The first mechanism is believed to be a major cause of Mnl\ 
mutations, and the second mechanism is believed to be the cause of mtMSI. 
Indeed, in some types of cancers, microsatellite sequences are preferentially affected due 
to slippage during the replication process (lonov et al, 1993; Aaltonen et al, 1993; 
Thibodeau et al, 1993). These replication error phenolypes are related to functional loss 
of mismatch repair (MMR) genes, in eluding the hMSH2, hMLHl, hPMSl and hPMS2 
genes (Mason et al, 2003). On the other hand, in the mitochondrial genome, the MMR 
system has been found only in the yeast strains, in which MSHl and MSH2 are 
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separately involved in mitochondrial and nuclear DNA repair systems，respectively 
(Reenan and Kolodner, 1992). No MSHl homologue has been found in mammalian cells 
and therefore, it remains uncertain whether an MMR system plays a role in the 
maintenance of mammalian mitochondrial genome. But according to the 
recommendations and guidelines reported for colorectal cancers (Boland et al, 1998)，the 
form of genomic instability associated with defective DNA mismatch repair in tumors is 
to be called MSI. It cannot be confirmed whether the so-called mtMSI as well as the 
alterations of D310 are true MSI or not, for there is no evidence showing the alteration 
was caused by defective mismatch repaired. If no evidence showed that the alteration was 
caused by MMR gene malfunction, the alterations of D310 cannot be considered as true 
MSI. More investigations should be performed to clarify whether these mutations are true 
MSI or not. 
Damage by ROS and lipid peroxides combined with Poly error repair seem to be the 
mechanisms subjacent for mtDNA mutation. mtMSI might depend more on the Poly 
mismatch repair than on damage by ROS. Polymerase y (POLy) carries out the mtDNA 
synthesis. Since this process is error-prone due to a deficiency in the proof-reading 
activity of POLT, it causes slippage for the poor fidelity when elongates repetitive 
sequences, this enzyme has been assumed to be involved in C- tract and other MS 
production. Thus, the combination of increased DNA damage by free radicals and 
deficient base repair by Poly could explain the mutations detected in the D loop region. 
‘ And Slipped strand mispairing followed by deficient repair is the mechanism accounting 
for the origin of MS repeat variants (Bianchi et al, 2001). Although the role of these 
factors in the induction of slippage misp airing is not clear, the moderate increase of 
mtMSI in cancer cells compared with the spontaneous rate observed in gerailine cells 
(16-fold versus the 216-fold detected in Mnll mtRFLPs) emphasizes that mtMS allele 
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changes in breast cancer are mainly due to Pol y errors and, to a lesser extent, 
ROS-induced DNA damage. The presence of mtMSI may have little connection with the 
deficicency of MMR. The combination of increased DNA damage by free radicals and 
deficient base repair could explain the increased mutations detected both in the mtDNA 
coding region and the D-loop region. But there should be some differences between 
mechanisms of mtDNA alteration and/or repair in different mtDNA region during 
carcinogenesis. Because of the low frameshift fidelity of the DNA polymerase gamma 
that carries out the mtDNA replication, slipped strand mispairing followed by deficient 
repair is the mechanism accounting for the origin of the MS repeat in D310. Hence, the 
occurrence of mtMSI in D310 may derive mainly from erroneous replication, whereas 
point mutations in the coding region like CytB gene may be attributed to oxidative 
damage caused by reactive oxygen species. 
p Although no human niitochondrial MMR gene has been discovered, it is also possible 
that maintenance genes in the nuclear genome may also play a role in the maintenance of 
mitochondrial DNA integrity. And the presence of mtDNA alterations may reveal some 
underlying defect in the maintenance and repair of both mtDNA and nDNA. Therefore, 
mitochondrial C-tract alterations would then be seen as epiphenomena related to 
alterations in the maintenance of genetic stability. It is possible for the alterations in 
mtDNA to serve as a general marker for genetic alterations. It has been reported that it 
can be used as clonal markers in multicentric hepatocellular carcinoma and can be 
detected in plasma and other paired bodily fluid as mentioned before. 
To clarify whether these mutations reflect genomic instability or not, the correlation of 
D310 polymorphism patterns (the proportion of those with 7 cytosines and those without) 
their with the c-tract mutation in both HCC tissues and non-tumorous tissues group were 
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investigated. By comparing polymorphism patterns in those that had alteration and those 
without (Table 9，10), it can be concluded that the 7 bp cytosine type (C7) of C-tract is 
less susceptible to C-tract alteration in both the tumorous and non-tumorous liver tissues. 
So 7-C repeat is the most common and stable polymorphism type of C-tract in Chinese 
HCC. Another interesting finding occurred in the 2 cases (case 96 and 397), which 
carried big deletions in the C-tract, with no other mutation found in the other 5 genes 
observed. Case 397, in particular, had no alteration in all the 5 genes. This is in 
concordance with the report from Maximo et al (2001) and implies that large deletion of 
mtDNA has an inverse relationship with both nDNA and mtDNA mutations. Moreover, 
Lucia et al (2000) reported that at position 309, a longer poly C tract length was strongly 
associated with a higher probability for heteroplasmy and rapid segregation between 
generations. They pointed out that the length of C-tract might play some roles in 
carcinogenesis. Based on these findings, it is now clear that the length variations or 
mutations of the D310 region do reflect genomic instability and closely associate with 
mtGI. 
The 7 Cytosine repeat might be the most common and stable polymorphism type of 
C-tract in Chinese HCC. When compared with the results from Sanchez-Cespedes et al 
(2001), it seems that the most frequent type of C-tract in Caucasians was 8 cytosines. 
Thus it can be hypothesized that in specific population, the most common haplotype of 
C-tract of mt DNA is also most stable for them. It may be a consequence of nature 
- s e l e c t i o n or a difference in age or haplotype. 
Phylogeographic difference of mtDNA among humans has been reported, polymorphism 
in mtDNA review human haplotypes, and anthropologist use it to trace the human ethnic 
migrations and revolution (Yao et al, 2002; Ingman et al, 2000; Macaulay et al, 1999). 
HCC is more endemic in certain geographic region and ethnic groups, so their 
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polymorphic type of c-tract might reveal different predisposition to HCC. First, the 
constitution of the C-tract polymorphic pattern between HCC tissues and adjacent 
non-tumorous tissues were compared (Table 8), but no difference was found. Thus, no 
C-tract polymorphic type has a connection with HCC at the somatic level. Subsequently, 
the difference of C-tract types in PBMC between HCC patients and normal subject was 
assessed (Table 11). There was no difference of polymorphic type of C-tract at the 
germline level. This implies that no specific predisposition to HCC exists in different 
polymorphic type of C-tract. The age and gender difference of polymorphic types were 
also compared, but no significant difference were observed (data not shown). Therefore, 
although certain D310 polymorphism type at both somatic and germline level may be 
associated with increased susceptibility towards HCC, this was not supported by current 
evidence. 
It is not yet clear whether sequence variants of the D310 region would lead to alterations 
in mtDNA replication. In this research, most of the alterations in D310 detected in the 
tumor DNA were 1-bp deletions/insertions, and almost all were in the polymorphic length 
range between 7-C and 9-C. A few tumors did show unusual variants (6-C and 10-C), 
which may be associated with tumorigenesis or maternally inherited rare polymorphisms. 
Some severe alterations could lead to functional impairment of the mitochondria and 
somehow promote a growth advantage for the tumor cell. Moreover, at least 2 HCC 
tissues harbored big deletion (9 bp and 10 bp), which may be mutations that originate 
‘ during tumor development as suggested by Nishikawa et al (2001). It is very possible that 
severe D310 C-tract length variations may have an important role in the regulation of 
• mtDNA metabolism. The D310 C-tract area lies in a conserved sequence block that 
contributed to persistent RNA-DNA formation and presumably controls mtDNA 
replication and transcription, it is the binding site for numerous molecules such as DNA 
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and RNA polymerases and other transcription and regulatory factors and thus may well be 
subjected to various pressures (Saccone et al, 1991). HVRII is probably the more 
important functional part of the control region because it contains the origin of heavy 
strand replication (Chang et al, 1985). And the CSBs that have been suggested to serve as 
control sequences involved in the transition from primer RNA synthesis to DNA 
synthesis (Walberg et al, 1981). It is possible that severe D310 C-tract variations may 
lead to altered replication and transcription of mtDNA, as a result, may cause over- or 
down- expression of respiratory chain polypeptides and change electron transport. As a 
consequence, it may confer a growth and/or survival advantage to tumor cells, increase 
mitochondrial oxidative stress and produce more ROS，which may lead to the impairment 
of nuclear DNA, or the disruption of the apoptotic process induced by mitochondria This 
contributes to neoplastic transformation. From Figure 7 and 8, much higher heteroplasmy 
had been observed in HCC tumor tissue in case 397 with a 9bp deletion in the D310 
^ region and case 96 with a lObp deletion when compared with case 387 and 39. It suggests 
that mtDNA of the cases 397 and 96 obtained a more rapid replication, and gave rise to 
‘ more heteroplasmic sequences for insufficient repair during rapid replication. 
On the other hand, minimal D310 C-tract frame shifts of one or two base pairs are 
common polymorphisms in the population. Almost all the alterations in D310 were in the 
polymorphic length range, which lay between 7-C and 9-C, so many investigators 
consider it hard to determine D310 length variants in tumors could lead to functional 
changes of the mitochondria. Conversely, It was found in the present study that the 
C-tract of 7 bp cytosines was the most stable polymorphic type of Chinese HCC tissue 
against C-tract mutation. These observations suggest that alterations in this region may 
play an important role in tumoriogenesis. Studies of mitochondrial degenerative diseases 
showed that mutant mtDNA must represent >80-90% of cellular mitochondria content to 
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cause a clinical phenotype (Chomyn et al, 1992; Attardi et al, 1995; Boulet et al, 1992). 
This threshold is likely to differ between mutations in the control and the coding regions. 
However, they are present in low-level heteroplasmy in normal tissue, suggesting that 
these minimal changes are unlikely to cause disease. But when they become 
homoplasmic, as in cancer tissue, they may affect the replication and transcription of 
mtDNA and may cause a clinical phenotype. 
Big deletion is not a common phenomenon in the mtDNA mutation in cancer while it is 
abundant in ageing or degenerative disease (Chomyn and Attardi, 2003), only two 
deletions harbored more than 5bp deletion (case 397 and 39) were found this study. There 
were several interesting points found when further analysis was performed to these two 
deletions. First, it was intriguing that the level of heteroplasmy in those cases harboring 
bigger deletions was much higher than those with smaller alterations. It may suggest that 
„ medina which have big deletions in the C-tract obtained a more rapid replication, and 
give rise to more heteroplasmic sequences for insufficient repair during rapid replication. 
This notion is supported by recent data from Diaz et al (2003), which indicated that 
human mitochondrial DNA with large deletions repopulates organelles faster than 
full-length genomes under relaxed copy number control. Second, no mutation was found 
in the other 5 coding, genes in these two cases. This is in concordance with the report 
from Maximo et al (2001), whose data implied that large deletion of mtDNA has an 
inverse relationship with both nDNA and mtDNA mutations. It may then be concluded 
that-the length variations or mutations of the D310 region do not only reflect genomic 
instability but also closely associate with the repopulation of mtDNA. It thus may play 
some role in carcinogenesis. 
Apart from case 397 and 39, most of the identified D310 C-tract mutations in this study 
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were homoplasmic. Polyak et al (1998) also found that 10 of 12 cases of colorectal 
cancers showed mtDNA homoplasmic mutations. Mitochondria of tumor cells 
proliferated selectively when such cells were fused with normal cells (Shay et al, 1990; 
Taanman et al, 1999), although hepatocytes contain hundreds of mitochondria and each 
mitochondrion contains 1-10 genomes (Wallace et al，1992). It may be due to certain 
mutant mtDNA molecules exhibit a replicative advantage. Two opposite hypotheses have 
been raised to explain the predominance of homoplasmic versus heteroplasmic-mutated 
mtDNA in cancer cells. According to the report by Shay and Werbin (1987)，under 
particular environmental conditions, some of the mt mutations may result in selective 
advantage, enabling the cell(s) harboring the mutation to outgrow other cells in the 
population and also allowing the mtDNA with the advantageous mutation to outgrow 
other mt genomes in the cell. In contrast, Polyak etal (1998) proposed that mt genomes 
with mutations that affect their functional efficiency overreplicated to maintain a normal 
OXPHOS pathway. Through the thousands of generations required for tumor progression 
and expansion, the most overreplicated mtDNA molecule(s) may easily replace other mt 
subpopulations, giving rise to homoplasmy. 
The mechanisms of mitochondrial replication and segregation are still unknown; several 
theories have been proposed to address it. These include: the bottleneck, 
clonal-selection, and random-segregation theories. The bottleneck theory proposes that 
only a small fraction of mtDNA molecules from a large population are sampled for 
transmission and amplification. However, as it is thought to be occuring only during the 
early stages of oogenesis (Lightowlers et al, 1997), it cannot explain the expansion of 
somatic mutations. The clonal-selection theory proposes that certain mtDNA mutations 
may confer a selective advantage or disadvantage for the host mtDNA copy. MtDNA 
mutants that confer disadvantages to the cell would be eliminated, whereas those that 
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possess survival advantage are propagated. The random theory proposes that somatic 
mtDNA mutations accumulated in tumours is the result of random genetic drift (Coller et 
al, 2001; Jones et al, 2001). This means that the pre-existing sequence variants, which 
could be present at a low level among the heteroplasmic population of mtDNA in the 
progenitor cells could outgrow other mtDNA molecules without any selection, after the 
hundreds or thousands of cell division cycles, and lead to the clinically manifested 
phenotype. Since many somatic mutations were found in mtDNA sequences without 
functional significance, for example, within the D-loop region, the presence of somatic 
mtDNA mutations in tumours might not necessarily lead to mitochondrial dysfunction. In 
this view, random genetic drift could satisfactorily explain the occurrence of somatic 
mtDNA mutations during carcinogenesis. A more detailed treatment of these ideas has 
recently been presented by Chinnery et al (2002). Recent results showed propagation of 
D310 C-tract frame shift of one cytosine insertion in human adult retinal pigment 
” epithelial (ARPE)-19 cells after 7 days of exposure to 2 DNA-damaging agents，whereas 
the other induced variants were eliminated (Mambo et al, 2003). Their findings are 
consistent with the selection theory or nonrandom segregation and further show that this 
process may be very rapid. They also found mtDNA-damage profile depended on the 
region, the highest frequency of homoplasmic somatic mutations located in the C-tract. In 
the mammalian mitochondrial systems, all of the proteins known to be involved in DNA 
replication are encoded in the nucleus. Thus alterations and deficiencies in mtDNA 
replication must arise from mutations in mtDNA regulatory sequences and nuclear gene 
defec^ts. The pathogenic role of this mutation in tumorigenesis is currently still unknown. 
More studies on the relationships between nuclear-encoded proteins and their mtDNA 
target sequences could result in strategies to manipulate genotypes within cellular 
mtDNA population (Clayton, 2000). 
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In this section, mtDNA D310 C-tract alterations were observed frequently in Chinese 
HCC tissues, and the D310 region was confirmed as a mutation hotspot in HCC. Since 
D-loop region of mtDNA is important in the replication process of mitochondria DNA, 
and the length variations or mutations of the D310 region were closely associated with 
mtGI, it could potentially be used as a novel tumor marker. 
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4.3 mtDNA mutation in coding region 
All the genes in the coding region are directly involved in the synthesis of respiratory 
chain polypeptides. Thirteen polypeptides of the mitochondrial OXPHOS complexes are 
encoded by mtDNA. The polypeptides include 7 (NDl, -2, -3, -4, -4L, -5, and -6) of the 
43 subunits of Complex 1, 1 (CytB) of the 11 subunits of Complex III, 3 (COI, 11, and III) 
of the 13 subunits of Complex IV, and 2 (ATP6 and 8) of the 16 subunits of Complex V. 
In this research, NDl , ND4 and ND5 of Complex I, CytB of Complex III, COII of the 13 
subunits of Complex IV were studied. The results showed that the frequency of mtDNA 
mutations in the coding region in HCC was also substantially greater than that detected 
previously in the other types of cancer (Polyak et al, 1998; Fliss el al, 2000; Nishikawa et 
al, 2001). Results from whole genome mutation suggested that the D-loop and the CytB 
gene were the preferred mtDNA mutation zones in HCC. Liu et al (2001) reported 
similar results in ovarian cancer those regions of preferred mtDNA mutation including 
‘ the 16S and 12S rRNA genes, the D-loop and the cytochrome b gene. 
The Wilcoxon signed-rank test indicated that there were significant differences in 
mutation rate between CytB and Coll, NDl, D310. Together with findings from Liu et al 
(2001)，CytB gene has been reported to be the most frequently mutated gene in the 
coding region in this study. Since all the regions in the coding area as well as D310 are 
exposed to the same mutagens, ROS, the difference in the mutation rate reveals different 
vulnerability to mutagens (freeradicals) and different efficiency in DNA damage repair. 
CytB gene is the area in the coding region that is particularly susceptible to mutation, and 
as a consequence, this zone has the highest potential to have mutational hotspots in the 
mtDNA coding region. 
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There were 9 alterations (90%) in nucleotide 14766 in the 10 CytB genes examined. This 
site can be undoubtedly considered as a hotspot. Eight out of the 10 CytB genes were 
detected to have a C14766T polymorphism and a C14766A mutation. The database 
(MITOMAP) was searched and consequently, two whole sequences (China-AF72, 
China-AF73) of Chinese mtDNA genomes were found and both harbored C14766T 
alteration. Both of these two were normal subjects, so most Chinese CytB sequences at 
the nucleotidel4766 are T，and C14766T is a polymorphism according to the database. 
Therefore, it could be concluded thai nucleotide14766 T is consensus in Chinese. The 
possibility of np 14766 in the CytB as a mutational hotspot was excluded. The remaining 
one alteration at this site, CI4766A in case 111, is a true mutation, which cause an 
isoleucine to an asparagine. The impact of this mutation on the protein of ATPase was 
further analyzed by using a set of software packages named Expert Protein Analysis 
System on The ExPASy 躲X.9Ig). From the prediction of this software 
(using software SignalP), the signal peptide and the cleavage site were possibly 
unchanged, transmembrane helices were predicted as the same and the possibility of 
‘ export to mitochondria was also very similar (data not shown). ExPASy was also utilized 
to elucidate the biochemical effect of CI4766A as well as C14766T. It was predicted that 
along with these alterations, there were no new restriction sites generated and the seven 
strong transmembrane helices were found to be the same (data not shown). Moreover, the 
possibility of export to mitochondria was also very similar. Thus, there is no significant 
change found in the mutated subunit. 
In addition, based on the results of whole genome mutation, the gene Col and ATPaseS 
should also be considered. But there were no consistent mutation/alteration in Col from 
our study based on the whole genome mutation, except for a silent polymorphism, 
C7028T, which was found in 3 of the 5 genomes. But it could not be considered with 
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biochemical importance. 
A8452T has been considered to be another potential hotspot for mutation. Three in the 
five cases with whole genome had been sequencedwere found to carry this mutation. 
A8452T alteration changes the theronine in the position of 37 to isoleucine in the 197 
amino acids in ATP synthase 8. The change of protein property of A8452T was analyzed 
in the same way as done in C14766T, and no alterations in both the transmembrane 
helices and their possibility of export to mitochondria were observed. However, after the 
theronine changes to isoleucine, the mt ATP synthase 8 becomes a little more 
homogeneous to the nuclear ATP synthase. The specific biological significance of this 
mutation is not clear. This region was then being screened in 20 PBMCs of normal 
subjects and 20 cases of HCC tissues with their paired non-tumorous tissues. It is 
surprising that none of these 60 cases were found to harbor this mutation. As a result, 
^ 叩8452 was proved unlikely to be a mutational hotspot although further studies should be 
done to clarify the significance of this mutation. It is interesting that we cannot find the 
‘ same mutation in the following 60 cases while it occurred in four of the five whole 
genomes. This may due to the sampling error for a small sample size of five in the whole 
genome study, and as sample size increased, the mutation rate detected in this zone 
should become closer to the true nature. Nevertheless, it should not be regarded as a 
hotspot. 
In this section, only one deletion bigger than 5 bp has been found and no large deletion 
(>100bp) have been observed. A 9bp deletion at np 8281-8289 in MTNC7 was observed, 
which is located in np 8270-8294, a non-coding region between MTC02 and MTTK. 
This 9-bp deletion was found to be adjacent to the so-called "Asian"-specific 10-bp 
deletion of mtDNA (8271-8281 9bp del) which was documented to be frequently deleted 
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in more than 700 subjects and has been used as a genetic marker to trace descent from 
peoples of East Asian origin (Redd et al, 1995; Soodyall et al, 1996). A geographic dine 
of the deletion frequency across modem Pacific Islander populations suggests that the 
deletion may be useful for tracing prehistoric Polynesian origins and affinities (Redd et al, 
1995). Both of the deletions are located in the intergenic region between the COII gene 
and the Lysine tRNA gene (COII/tRNALys intergenic region), but they are not consistent 
with each other. It also cannot be considered as a mutation hotspot. 
There were two other mutations occurred in the coding region consistent with previous 
recorded in the mitomap database. First, a G3316A in NDl caused alanine to tyrosine and 
has been reported in type 2 diabetes mellitus (type 2 DM), Leber's hereditary optic 
neuropathy (LHON) and progressive encephalopathy (PEO). Second, a T14783C 
polymorphism in CytB also found in breast cancer. 
m 
However, most of the mutations (144 out of 150) found in the coding region, like those in 
‘ the D-loop region, were new mutations, seldom of which were previously reported in 
other diseases and cancer. It suggests that the mutations observed were most likely 
"scattered" in origin. Konstantin et al (1997) also found the mutations were sporadic. 
They observed mutations could arise either from DNA replication error or from replicate 
bypass of DNA adducts created by reaction with endogenous factors, for instance, the 
elements of the oxygen and NO cascades. This may mean that either there is no common 
mutation in cancers or the mutations are sporadic. There is also another possibility that 
the mutations or alterations of the mtDNA coding region in HCC is unique and this may 
imply that there exist HCC specific variants. Nontheless, the possibility of finding a 
mutation hotspot is minimal. 
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It has been shown that mtDNA sequences with somatic mutations in some cases may be 
confused with nuclear pseudogenes of mtDNA sequences (Hirano et al, 1997; Wallace et 
al, 1997)，alth'ough this requires strong selection against mtDNA (Hirano et al, 1997; 
Li-Sucholeiki et al, 1999). To make sure that the mutations discovered did not originate 
in pseudogenes, I searched the public version of the human genome (BLAST, 
www.ncbi.nlm.nih.gov /BLAST/) for homologies to the mtDNA sequence of base pairs 
16.5 kb. Many pseudogene-like sequences homologous to the various parts of the coding 
region are present in the human nuclear DNA. None of pseudo- gene sequences, however, 
spanned the whole control region and thus could not be the source of our PCR products, 
which span the whole region. Moreover, the nuclear sequence with the highest homology 
to mtDNA was less than 50% homologous, which is consistent with the established 
relatively ancient origin of pseudogenes (Hu et al, 1994; Hu et al, 1995; Zischler et al, 
1995). In contrast, mutant sequences found in the section of whole genome mutation and 
coding region mutation contain mostly <10 base changes in PCR products which mostly 
more than 1 kb, i.e., were >99.0% homology. Even in the section of D310 mutation, 
‘ mutant sequences also contain mostly <10 base change(s) in a product of 306bp, the 
degree of homology were also >95.0%. Moreover, all the PCR products amplified were 
of exactly the same size as the desired fragments, which further excluded the possibility 
of contamination of nuclear pseudogenes. 
The possibility that some of the mutations found in individual cells were generated in a 
germ-line cell rather than in a somatic cell cannot be completely excluded, especially 
when HCC whole genome mutation was being studied. If some of the mutations reported 
here were low percentage germ-line mutations, they still must have undergone clonal 
expansion in the PBMCs of other HCC patients. 
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To sum up, mutations also occurred frequently in the coding region of mt genome, 
especially in the CytB gene. Their mechanism for mutation are possibly very samilar. 
However, no mutation hotspot was found in this region. 
J 
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4.4 Possible mechanisms of mtDNA mutation in HCC carcinogenesis 
The combination of increased DNA damage by free radicals and deficient base repair 
could explain the increased mutations detected both in the mtDNA coding region and the 
D-loop region. Coding region mutations like CytB gene may be attributed to oxidative 
damage ROS whereas the occurrence of D310 mutation may derive mainly from 
erroneous replication. . 
Increased levels of reactive oxygen are generated resulting from deficiencies in 
enzymatic activity of the respiratory chain complexes with altered amino acid sequences 
due to the mutations in the subunits encoding genes. This would lead to a series of 
outcomes with declined energy production due to: 1.leakage of electron from less 
efficient mitochondria transport chain; 2.declined in proton pumping from various 
complexes, capacitor effect and depolarization of mitochondria; 3.alteration of the 
‘mitochondria transmembrane potential; lowering the ATP production from ATP synthesis 
and release of calcium (Oaawa, 1995; Jaaltela, 1999). As electrons flow through carriers 
within the respiratory chain complexes during the electron transportation pathway 
through NADH ——>FMN——>Fe-S——>CoQ——>cytb——>Fe-S——>cyt Ci，about 
one to five percent of electron leaks through this chain and donates to molecular oxygen 
forming ROS. If they cannot be detoxified by defense mechanisms like MnSOD and 
glutathione peroxides, they may attack mtDNA and induce somatic mutations (mostly 
base substitutions) and strand breaks (Richler et al, 1995). The mutated mtDNA and 
alteration of mitochondria function would enhance endogenous ROS production by a 
positive feedback mechanism, further mtDNA mutations would be produced and 
accumulated, thus amplify pathological consequences in tumor (Ozawa, 1995; Kirches et 
a/, 2001). 
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Mitochondria are suggested to be a possible mediator of apoptotic tumor cell death and 
high concentration of free radicals are toxic and can initiate apoptotic cell death (Richter 
et al, 1995; Wallace, 1999). For instance, hydrogen peroxide, which originates in 
mitochondria predominantly from the dismutation of superoxide, causes oxidation of 
mitochondrial pyridine nucleotides and thereby stimulates a specific Ca^^ release from 
intact mitochondria. This release is prevented by cyclosporin A (CSA). Hydrogen 
peroxide thus contributes to the maintenance of cellular Ca^^ homeostasis. A stimulation 
of mitochondrial ROS production followed by an enhanced Ca^^ release and re uptake 
(Ca2+ 'cycling') by mitochondria causes apoptosis and necrosis. However, somatic 
mtDNA mutations, which may change sequences and structures in OXPHOS complexes, 
may only enhance ROS production moderately (Kirches et al, 2001). This moderately 
increased ROS concentration may become a mitotic stimulus in tumor cells rather than a 
apoptotic stimulus (Li et al, 1997). Moreover, this decline in respiratory function in 
' tumor cells would inhibit apoptosis signing pathways. 
The D310 C-tract is crucial in controlling mtDNA replication and transcription, it is 
possible that some D3.10 C-tract (or D-loop) variations may lead to altered replication 
and transcription of mtDNA, and this may confer a growth and/or survival advantage for 
those cells. 
Besides, strand breaks by ROS would form mtDNA fragments (transposable elements), 
which escape from mitochondria and integrate into nDNA (Richter et al, 1995). This 
integration may inactivate genes for the maintenance of normal growth control or activate 
a proto-oncogene. Thus transforming cells to cancerous state (Hu et al, 2001). 
1 2 6 
To conclude, with respect to the role of mtDNA mutation in the process of carcinogenesis, 
the following hypothesis is proposed: mutations in both the mtDNA coding region and 
the D-loop region could be caused by increased DNA damage from oxidative pressure 
and deficient base repair. D310 C-tract (or D-loop) variations confer a growth and/or 
survival advantage to cells and lead to altered replication and transcription of mtDNA. 
Meanwhile, the D-loop mutations together with those in the coding region may cause 
over- or down- expression of respiratory chain polypeptides and alter electron transport. 
Subsequently, more ROS may be produced and thus increase the mitochondrial oxidative 
stress. Finally, a vicious circle is formed; the faster the growth, the more severe mutations 
in C- tract and coding region are generated. This, thereby, enhance endogenous ROS 
production and reduce the respiratory function and ATP production. These changes may 
lead to the impairment or the disruption of the apoptotic process and stimulate the 
mitosis. Besides, mtDNA fragments integrate into nDNA may inactivate normal growth 
control genes or activate a proto-oncogene. All these may contribute to tumor initiation, 
"promotion or progression. 
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4.5 Prospective projects for future research 
4.5.1 Function of C-tract of D310 
The C-tract of D310 has been observed as a mutational hotspot in HCC, with a mutation 
rale of 22%. Together with other investigations, this region are a common hotspot in 
HCC, thyroid cancer, gastric cancer, cervical cancer, bladder tumors, breast cancer and 
endometrial neoplasia (Hiyama et al, 2003; Tong etal, 2003; Mambo etal, 2003; Parrella 
et al, 2003; Parrella et al, 2001). Therefore, D310 mutation is highly likely to be involved 
in carcinogenesis. 
Habano et al (2000) believe in that mitochondrial MSI in gastric carcinomas might play 
an imporlanl role in the lumorigenesis of these carcinomas in that the C-tract region 
controls the transcription of the mtDNA heavy strand. However, Simo Schwartz and 
Manuel Perucho (2000) doubly disagree with it. In their opinions, there was no evidence 
thai these mutations reflect genomic instability or that the mutations are functional. On 
the contrary, the present study concluded that the C-tract of 7 bp cytosine was the most 
stable polymorphic type of Chinese HCC tissue, and that large deletion of D310 has an 
inverse relationship and mtDNA mutations. So, these mutations could reflect genomic 
instability. . 
Indeed, length variations of this repeat (6 <n >12) and heteroplasmic populations of 
mitochondria have been detected in normal tissues by Hauswirth et al (1985) and Comas 
e/ al (\99S). They think insertion/deletion mutations observed in the noncoding (C)8 tract 
most likely lack function and they proposed that the mutations in the (C)8 tract in the 
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regulatory region of the mitochondrial genome are detected because of tumor clonality, 
which implies intracellular clonal variation and evolution (Streisinger et a/,1966; Polyak 
et fl/,1998; Hauswirth et a/,1985; lonov et a/,!993). Although this region controls the 
transcription of the mtDNA heavy strand, variations in length of this repeat do not seem 
to affect the level of transcription (Comas et al, 1995). 
Whether the mutations are functional would require further study. I propose to first use 
4-nilroquinoline 1-oxide (4NQ0) and 紀"-butyl hydroperoxide (BHP) to treat human 
Hep3B cell line. After exposure to the damaging agents, the cells were either harvested 
immediately or incubated for an additional 4 or 24 h in complete medium without the 
damaging agents to allow lime for repair. Then quantitative real-time PGR and real time 
RT-PCR could be performed to evaluate the copy number alterations of D310 and the 
coding regions, i.e., NDl-5, Col-Il, CytB, RNR2, ATPaseS and ATPase6 before and after 
the treatment. Meanwhile, the respiration subunits, namely, NDl-5, CoI-II, and CytB will 
be examined by immunochemistry. The D310 C-tract were cloned and variants could 
analyzed by PGR amplification and sequencing. Finally, the relationship of D310 variants, 
other regions and mtDNA copy number could be analyzed to address the D310 function. 
During the period of cell culture, c-DNA microarray could be combined with 
2-dimentional gel electrophoresis and mass spectrometry to investigate the alterations at 
transcription and translation level, and high throughput information about nucleus -
mitochondria communicationcould also be obtained. Additonally, prospective study 
during the course of cell culture by using TUNEL assay could be applied to address the 
relationship of variation in the D310 C-tract and apoptosis. 
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4.5.2 Function changes of mtDNA coding region mutation 
Although software was. employed lo predict the functional changes in the protein caused 
by mtDNA mutations in the coding region such as CI4766A and A8452T. Real 
molecular and biological experiments should be carried out to identify if the amino acid 
changes would greatly affect the secondary and tertiary structures of proteins, which 
associated with their function. But it is difficult to confirm their fuction changes and 
whether these mutations are pathological, as was recently indicated by Chinnery et al 
(1998). 
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4.5.3 Detection of D310 C-tract mutation in patients' plasma 
The data suggests that the C-tract of D310 might be the mutational hotspot and is most 
constantly mutated in HCC. Therefore, its mutation may have the most potential to be 
used clinically. Patients suffering from malignant diseases have been shown to have 
increased amounts of cell free nucleic acids in their circulation (Johnson et al, 2002). As 
genetic and epigenetic alterations are increasingly characterized in different types of 
tumors, such changes can be used to detect tumor-derived nucleic acids in the circulation 
including D310 C-tract mutations in HCC (Sanchez-Cespedes et al, 2001; Johnson et al, 
2002). Nomoto et al (2002) detected mutant mtDNA in 8 of 10 tested paired plasma 
DNA samples using oligonucleotide mismatch ligation assay, and found that mtDNA 
mutations within the D-loop control region provides a molecular tool for the 
determination of clonalily. In addition, Okochi et al (2002) observed that 5 of 15 paired 
serum samples (33%) contained the same mtDNA mutations as primary tumors. He 
concluded that mtDNA mutation may prove effective for detection of tumor DNA in the 
- s e r u m and may be a novel tumor marker of HCC. However, apart from D310 C-tract 
mutation, all the other mtDNA mutations are sporadic. In this regard, detection of D310 
C-tract mutation in patients' plasma or serum will be more of clinical significance. But a 
difficulty in oligonucletide design exists (Nomoto et al, 2002), and the biological 
functional changes of this mutation is not yet clear. We cannot detect the mutation by 
direct sequencing for the mutated mtDNA is rather diluted (1: 200-500) by the normal 
mtDNA in the circulation. Only after these crucial problems are determined, can 
detection of D310 C-tract mutation in patients' plasma or serum be effectively applied in 
the clinical setting. 
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4.5.4 Relationship between nMSI and mtMSI 
The connection between nMSI and mtMSI is intriguing in that studies have addressed the 
issue of mtMSI in human cancers cannot reach concordant conclusions about the 
relationship between the instability of nuclear and mitochondrial genomes. Habano et al 
(2000) claimed that there were a significant positive association between the MSI of 
nDNA and mtDNA, and explained that the gene products of the mismatch repair (MMR) 
genes whose in activation is responsible for nMSI have no any putative mitochondrial 
localization signal, and they can not be delected in the mitochondrial component 
immunohistochemically. Thus, Habano etal acknowledge that the molecular mechanisms 
by which nuclear and mitochondrial genomes simultaneously become unstable in gastric 
but not in colon carcinomas are unknown. Bui Simo Schwartz and Manuel Perucho (2000) 
tdid not agree. They have performed a more extensive screening of gastric cancers for 
mutations in ml DNA and found no association of somatic mutations in repetitive 
sequences between nDNA and mtDNA. And they interpreted these results as indicative 
- t h a t alterations in mitochondrial repeat sequences did not represent genomic instability, 
but the intrinsic mutability of these reiterated sequences. When no repair activity is 
present to correct spontaneous slippage errors of replication by strand misalignment 
(Streisinger et al, 1966) and mutations rapidly accumulate. However it could not explain, 
why the Ce was seldom altered and why the alteration had focused on the C? in the D310 
C6TC7 tract. Therefore, it appeared that the intrinsic mutability of these repetitive 
sequences was not the only evnet. From the present data, the D310 MSI was associated 
with the coding region mutation; il is thus concluded that C7 of D310 actually represented 
genomic instability, except the Ce tract. 
Schwartz et al (2000) also demonstrated contrary result concerning association between 
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mtMSI and nMSI. Because early cancers rarely showed nMSI or mtMSI, a high 
proportion of advanced cancers with both MSIs might affect data in Habano's study 
(2000). One possible mechanism for this positive correlation is that nuclear and 
mitochondrial DNA share the same MMR systems. However, in their additional study 
(Habano et al, 2000 b), mitochondrial (C)n sequences were consistently stable in cultured 
cancer cell lines, independent of the MMR gene status (hMSH2, hMSH6, and hMLHl). 
Therefore, they ruled out the possibility that the mtMSI results from nuclear MMR gene 
defects. Another mechanism may be explained by a "mutator mutation" theory, like the 
hMSH3 and hMSH6 gene mutations in MSI-positive cancers. They suggested that certain 
mtDNA repair genes, which were located in nuclear genome, were inactivated through 
coding frameshift mutations associated with nMSI. This model could explain the positive 
correlation between nMSI and mtMSI, although this is still speculative. 
Therefore, I propose that more investigations should be given to address the relationship 
of MSI between the two genomes in various cancers, say, C-tract of D310 and BAT25, 
- B A T 2 6 , D5S346, D2S123 or D17S250，to determine if mtMSI results from nuclear MMR 




This Mphil. thesis describes the mtDNA mutation in HCC of Chinese patients and 
discusses its role in HCC carcinogenesis and potential use of D310 as a tumor marker. 
HCC is one of the leading causes of cancer deaths in the world, and ranks as the 2nd most 
common type of cancer in Hong Kong. However, it is frequently diagnosed at an 
advanced stage, which is associated with very limited therapeutic options and, hence 
relatively poor prognosis. HCC carcinogenesis is considered as a multistep process and 
the earliest presentation should be its molecular transformation, so there is a need to 
investigate the molecuilar vents leading to HCC and determine molecular tumor marker 
for the early detection of HCC. Recently, frequent mitochondrial DNA (mtDNA) 
mutations have been found in various diseases including cancers. Its mutation rate is 10-
to lOO-fold higher than that of nuclear DNA (nDNA), rendering it a massive effect over 
the nDNA mulalion in the early detection of hepatocarcinogenesis. As a result, it has 
- e m e r g e d to be a potential molecular tumor marker. 
In this study, I first directly sequenced the whole mtDNA genome of four cases of HCC 
and one HCC cell line (Hep3B) to assess the frequency and pattern of mtDNA mutations. 
All the five cases of the whole genome were found having D310 C-tract mutation 
together with other altkations in both the D-loop and the coding region, with an 
alteration rate of 7.5 and 1,4 per one thousand base pairs, respectively. We found that 3 
genes, RNR2, COI, and CytB, were 100% alterated, and 4 other genes, ND2, COII, ATP8 
and ND5 were 80% altered. The data confirmed that there are frequent mutations located 
in the mtDNA, especially in the D310 C-tract of the D-loop. Most of the alteration are 
homoplasmic and usually G-C, A-T mutations. It supports the idea that ROS oxidative 
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damaging is associated with most of the mutations. The pattern of mutations in HCC 
mitochondrial genome was determined and potential mutational hotspots were identified. 
Then I tested 55 cases of surgically resected HCC and their corresponding non-tumorous 
tissues in Chinese HCC patients. I first used PCR-PFLDA to test the C-tract region and 
then used PCR-SSCP to examine five encoding the respiratory chain subunit genes of 
mtDNA, namely, CytB, Coll, NDl, ND4, and ND5, Subsequently, DNA samples from 
the cases with the C-tract and other five genes mutations were subjected to direct 
sequencing. Among them many new mutations were identified. Twelve out of the 55 
cases (22%) of the HCCs analyzed harbored somatic deletions/insertions at the C-tract. 
For the five respiratory chain subunit genes, 47.3% of CytB, 34.5% of ND4, 29.1% of 
ND5, 21.8% of NDl and 16.4% of Coll were found to harbor mutations. These data 
further suggested that mtDNA are frequently mutated in HCC and that the D-loop of 
ml DNA, C-tract in particular, is a mutational hotspot in Chinese HCC for the earlier 
detection and diagnosis for clinical use. 
Based on our data, a series of crucial issues in the field of mtDNA mutation and cancer 
were addressed. For example, the data support the idea that mtDNA alterations or 
mutations result from the reactive oxygen species (ROS) continually generated in the 
mitochondria, especially during OXPHOS. Most of the identified mutations in mtDNA 
were homoplasmic, possibly because certain mutant mtDNA molecules exhibit a 
replicative advantage. We also found that the C-tract of 7 bp cytosine was the most stable 
polymorphic type of Chinese HCC tissue against C-tract mutation, so the length 
variations of D-310 c-tract should reflect genomic instability. 
By inspection of these mutations, the study provides new insights into the role of mtDNA 
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mutation in HCC genetics and HCC carcinogenesis. I propose to further investigate the 
function of C-tract in D310, how its mutation affects the replication and expression and 
segregation of mutant mtDNA, and then how it is related to the proliferation and 
apoptosis of cancer cells. Although the length variations of D-310 c-tract is suggested to 
reflect genomic instability, whether it is a true mtMSI or just merely a mutational hotspot 
is not currently clear. It is worthy to investigate the relationship between mtMSI and 
nMSl in various cancers, to make sure whether or not mtMSI results from nuclear MMR 
gene defects and if there are yet unidentified mtDNA repair genes located in nuclear 
genome. After the roles of C-tract mutation of D310 in carcinogenesis is clarified, the 
detection of D310 C-tract mutation in patients' plasma or serum can then characterized 
and put into clinical utilization, specially, as a marker for the early of HCC as well as 
other cancers. Moreover, by manipulating it together with other mtDNA control regions, 
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